Energy conversion monitoring device, system and method
By using a light-based sensor system to detect cellular oxygen supply status at wavelengths of 685 nm and 850 nm, the problem of inaccurate monitoring of cellular oxygen demand in existing technologies has been solved, enabling efficient diagnosis and treatment of sleep-disordered breathing. This system is suitable for safe monitoring in various environments.
Patent Information
- Application Number
- CN201980076025.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2019-09-16
- Filing Date
- 2019-09-18
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2039-09-18
AI Technical Summary
Existing blood oxygen monitoring technology cannot accurately detect whether the cells' oxygen demand is adequately met or exceeded, resulting in health problems such as sleep apnea not being effectively diagnosed and treated. Furthermore, existing equipment is inconvenient to use in high-risk environments.
Employing a light-based sensor, the system detects cellular oxygen supply using 685 nm and 850 nm wavelength spectra, monitors cellular oxygen supply status via the energy conversion index (ECi), and provides real-time, non-invasive monitoring by combining an electron accelerometer and a temperature sensor. Data is transmitted via Bluetooth to a smartphone application for analysis.
It enables real-time monitoring of cellular oxygen supply, improves the diagnostic accuracy and treatment efficacy of sleep apnea, is suitable for safe monitoring in various environments, and reduces social costs.
Smart Images

Figure CN113301846B_ABST
Abstract
Description
[0001] Cross-references
[0002] This application requires September 16, 2019 The submitted serial number is 16 / 572106 The U.S. application claims priority September 18, 2018 The submission name is " Sleep Disordered Breathing Monitors, Systems and Methods "U.S. Provisional Application No. 62 / 732876 The U.S. provisional application is incorporated herein by reference in its entirety. Technical Field
[0003] Sensor devices, systems and methods for monitoring oxygen-related physiological functions of the human body are disclosed. Specifically, the sensor system of the present disclosure provides real-time and near real-time non-invasive monitoring of oxygen demand at the cellular level relative to oxygen supply. The system, device and method monitor the full range of oxygen-based physiological functions from "cellular hypoxia" (cellular hypoxia) through "just right" (aerobic metabolism) to "cellular hyperoxia" (cellular hyperoxia). Background Art
[0004] For example, monitoring during sleep Oxygen intake Current clinical methods are limited to indirect measurement via pulse oximetry Oxygen saturation of hemoglobin in the blood (SpO2), which indicates the oxygen supply in the blood, and Assumptions If oxygen levels in the blood are within the "normal range," vital organ tissues will be safely and effectively supplied with oxygen to meet cellular oxygen demands. However, through experimental and proof-of-concept (POC) clinical studies, it has been determined that the physiological stress and pathology associated with sleep-disordered breathing (SDB) occurs at the cellular level; not in the blood. The long-standing assumption of adequate cellular oxygen supply with "normal" oxygen-saturated blood has not been verified due to the lack of sensors that can discern whether cellular oxygen demands are being adequately met or exceeded.
[0005] Blood oxygen levels measure how much oxygen a person's red blood cells are carrying. Under normal conditions, the body carefully regulates blood oxygen levels to maintain a consistent range of oxygen-saturated blood. People with abnormal lung function may need to have their blood oxygen levels monitored to determine if treatment is working or needs to be adjusted. One way to test blood oxygen levels is with an arterial blood gas test. This test requires drawing blood from an artery, typically the wrist. The blood is then sent to a lab for testing. Another option is to use a pulse oximeter device. A pulse oximeter provides an estimate of the percentage of oxygen saturation in the blood with a margin of error of 2%.
[0006] While blood oxygen saturation is clinically important information, the adequacy of cellular oxygen supply relative to the cellular demand for oxygen is critical to maintaining vital functions and avoiding cellular damage. Several instruments known as "tissue oximeters" require measurement of tissue oxygen supply status by timed sampling of light absorption through the skin or deeper tissues; these signal variations are attributed to blood alone. Where the "peak" and "trough" signal sampling used in pulse oximeters effectively excludes signal variations due to capillary and venous blood and cellular chemistry, the timed sampling in "tissue oximeters" cannot exclude these major confounding factors. "Tissue oximeters" utilize Log spectroscopy as used in pulse oximeters. 10 The signals it detects are processed using a ratiometric calculation, calibrated with hemoglobin to produce a “tissue oxygen saturation” (StO2) percentage (0% to 100%) based on the assumption that the signal changes are due to blood. Under minimal stress conditions, the StO2 data respond generally like pulse oximetry. However, when blood flow to the monitored tissue is stopped and then restarted, the interpretation of the StO2 signal response as originating solely from blood becomes seriously flawed. The recorded amplitudes of the signal changes detected upon reperfusion (up to 20% full scale at 685 nm) are too large to be due to changes in oxygen saturation in capillary blood, which occupies less than 1% of the sensor’s optical path in the skin. The timing and direction of the spectral absorption response upon reperfusion are also inconsistent with blood volume or oxygen transfer from blood. Overall, these experimental results call into question the assumptions and methods currently applied to “tissue oximetry.”
[0007] Sleep disordered breathing (SDB) is a major health problem that is increasingly recognized in all age groups, from premature newborns to the elderly. The rising social costs of SDB and associated obesity include increased traffic accidents, loss of worker productivity, and increased incidence of major comorbid health problems including hypertension, heart attacks, atrial fibrillation, and stroke. The most typical SDB event is airway obstruction, which is due to relaxation of the tongue, soft palate, and throat muscles during sleep (obstructive sleep apnea (OSA)) and reduced central nervous system respiratory drive (central sleep apnea (CSA)). Once sleep apnea is diagnosed, the patient is typically prescribed an airway therapy device. Airway therapy devices include positive airway pressure devices, such as continuous positive airway pressure (CPAP) machines, which provide a stable airway pressure and are used under the assumption that the patient has the same persistent problem over time. Alternatively, automatic positive airway pressure (APAP) machines that adjust the pressure in a feedback control manner are most commonly used for OSA patients whose airway patency changes during sleep. CSA patients have difficulty with the timing and effort of breathing during sleep and are usually treated with a bi-level positive airway pressure (BiPAP) machine, which provides increasing pressure assistance for individual breaths. When reduced air flow resistance during exhalation is needed, a variable positive airway pressure machine (VPAP) is used. Oral appliance therapy may be appropriate for the treatment of mild SDB, but its effectiveness needs to be verified with individual users.
[0008] Several major areas of human disease are clinically recognized to have a strong statistical association (if not a direct causal relationship) with the occurrence of SDB, including ischemic stroke, atrial fibrillation, and heart attack. It has long been clinically hypothesized that there is a causal physiological relationship between snoring and the risk of hypertension or high blood pressure. However, polysomnographic (PSG) sleep studies, which include continuous monitoring of arterial oxygen saturation (SpO2) by pulse oximetry, do not detect or show consistent occurrences of decreased blood oxygen or hypoxemia during snoring. Snoring during sleep without a drop in SpO2 is currently not "rated" as a pathological event in PSG sleep studies because there is no association with decreased blood oxygen levels. Because snoring is not rated as an SDB event, airway pressure devices (such as CPAP and APAP devices) are not covered by most health insurance policies or Medicare (US National Elderly Medical Insurance) because snoring does not cause decreased blood oxygen. Hypoxic stress at the cellular level clearly occurs during snoring, but this is not detectable by PSG pulse oximetry.
[0009] It is statistically known that many other pathological processes are exacerbated by co-occurring SDB and may be alleviated if the patient's SDB is effectively treated. It is currently estimated that of the approximately 54 million adults in the United States (US) with SDB and / or SDB-related comorbidities, approximately 80% are currently undiagnosed or ineffectively treated. Published studies also include sudden infant death syndrome (SIDS), which is likely due to an infantile variant of SDB pathology, with a peak incidence associated with neurological development at approximately 2 months of age and extending to approximately 1 year of age.
[0010] The technical sophistication of the PSG sensor system is particularly limited in the case of newborns with SDB. All newborns may need to be effectively screened to ensure stable respiratory drive and functional airways during sleep to identify infants at increased risk for SIDS. Currently, approximately 3,500 U.S. infants die from SIDS each year, despite extensive efforts to educate parents about their infant's sleeping position, bedding, etc. Once identified, infants at risk need to be provided with a safe sleeping environment and continuously and effectively monitored during all sleep periods, including daytime naps.
[0011] The Collaborative Home Infant Monitoring Evaluation (CHIME) study from 1994 to 1998 included 1079 infants, many of whom were considered to be at higher risk than the baseline risk for SIDS because they were siblings of infants who had died from SIDS. This study provided strong evidence that SDB (including OSA and CSA) is a major factor in SIDS. Unfortunately, the micro-PSG monitoring system used during the CHIME study was so difficult and time-consuming to apply that some parents were reluctant to fully comply with the study protocol; this may have contributed to the five infant deaths that occurred while they were not being monitored.
[0012] After the CHIME study, the American Academy of Pediatrics issued a policy statement that discouraged the use of currently available technology for home infant monitoring for the purpose of preventing SIDS. The position of the academy is that no infant monitoring system can identify and alarm SDB events uniquely associated with SIDS in a sufficiently timely manner to help prevent death. Neonatal intensive care unit (NICU) cardiorespiratory monitoring technology is the only available option, and typically premature newborns who are still developing will be sent home when the baby still needs to be monitored for "apnea / bradycardia", which is one of the forms of SDB associated with premature infants. Existing NICU monitoring technology has low adaptability to adult monitors and is therefore unable to functionally identify the respiratory control, airway and cellular oxygen supply problems identified in the study, which seem to be unique to infants at risk of SIDS. In addition, because NICU monitoring technology is designed to assume that safe and effective operation requires the operator to be a qualified nurse or doctor, its mechanical and operational complexity poses a significant obstacle to effective use by parents at home. There remains an unmet need for an easily applicable, fully effective SDB monitoring and alert means that can be used to screen all newborns for risk of SDB and that can also be conveniently used by parents at home throughout their identified infants' SIDS risk period extending from about 1 month to about 1 year of age.
[0013] Additionally, many children and young adults snore during sleep; some also experience complete obstruction of their airways during sleep due to enlarged tonsils and adenoids. Effective diagnosis currently requires these children to undergo PSG studies, which can be very frightening for the child. Surgery to remove enlarged tonsils and adenoids (commonly called T&A surgery) to stop snoring during sleep carries risks and may not be covered by health insurance unless there is a formal PSG-based diagnosis of SDB and / or medical documentation of a specified number of Group A Streptococcus throat infections.
[0014] Unfortunately, even those who are diagnosed with SDB and currently use airway pressure devices during sleep may not be receiving fully effective treatment. Many factors are involved in this low diagnosis rate and marginally effective treatment, including: (1) the accessibility, high cost, and discomfort of PSG sleep studies in a sleep laboratory, which currently require prescription and home management of airway pressure devices, (2) the initial discomfort of treatment during sleep, and (3) the significant likelihood of suboptimal long-term management of treatment, primarily due to incomplete or lack of objective information beyond the PSG sleep study and initial titration of airway pressure device settings.
[0015] One of the common threads in the healthcare areas mentioned above is the unmet need for direct monitoring of cellular oxygen supply, which is not provided by pulse oximetry. This is also a major challenge in several major health problems including ischemic heart attack, ischemic stroke, organ transplantation and retinopathy of prematurity. It has long been theorized that cellular damage occurs primarily during the ischemic or hypoxic phase of the disease. Cellular adaptation to inadequate oxygen supply has not been considered a factor. However, current research evidence clearly indicates that the onset of reperfusion is the time when microvascular occlusion begins, followed by death of surrounding tissue. This correlation indicates that cellular adaptation may occur during the ischemic period, so that upon reperfusion with "normal" oxygenated blood, there is microvascular endothelial damage due to the relatively excessive oxygen supply, resulting in white blood cell adhesion and occlusion of capillaries and venules. Stage I retinopathy of prematurity (ROP) appears to occur during the rapid increase in blood oxygen from the relatively low fetal range to the "normal neonatal" level at birth, and during intensive care, which clearly indicates cellular adaptation to the previously much lower fetal oxygen supply rate at birth. Current studies also indicate that microvascular occlusion and cell damage occur during reperfusion of transplanted organs, which clearly indicates the adaptation of cells to much lower oxygen supplies during organ harvest and transportation. Therefore, reperfusion of ischemic vital organ tissues may benefit from a more gradual resupply of oxygen: starting reperfusion with recipient venous blood, then mixing in an increasing portion of arterial blood until the normally oxygenated arterial blood flow is tolerated without causing damage. Premature neonates may benefit from initial care starting with breathing gases that provide a "placental" range of oxygen availability, then gradually increasing the oxygen content until breathing air is tolerated without damage. An obvious unmet need in all of these areas is the need for a means of indicating the upper limit of cellular oxygen tolerance to help minimize or prevent these adverse treatment outcomes.
[0016] Pulse oximetry has known limitations during and after surgical anesthesia, where surgical blood loss and dilution of the blood with intravenous fluids can result in insufficient oxygen delivery to vital organs. Oxygen delivery during surgical anesthesia is typically maintained at the high end of normal levels, or even significantly in excess, in an attempt to provide a safety buffer against episodes of hypoxemia. Pulse oximetry cannot detect excess oxygen delivery and cannot provide warnings of potential or ongoing harm from excess oxygen. Pulse oximetry also has significant limitations in remote patient monitoring, post-discharge care monitoring, and chronic disease management. The awkward application site and motion intolerance of pulse oximeter sensors make them unsuitable for use as high-risk worker safety alarms required by military and commercial pilots, astronauts, divers, firefighters, underground miners, and other industrial workers in potentially toxic atmospheres. Summary of the invention
[0017] The disclosed devices, systems, and methods provide for the detection and characterization of the physiological components of SDB in a comfortable and easily wearable form factor that can be configured for all age groups. The use of sensors can help reduce the societal cost of SDB by: (1) improving the quality of life of patients with SDB by enabling optimal diagnostic testing in sleep laboratories and at home; All Ages The invention provides for the following purposes: (1) improving access to SDB diagnosis for individuals with chronic obstructive pulmonary disease (COD), (2) optimizing physiologic criteria that define payer coverage for airway pressure device therapy (and pediatric T&A surgery), (3) optimizing effectiveness and comfort of airway pressure device therapy using physiology-based feedback control, (4) validating effectiveness of oral appliance therapy, and (5) spot-checking and continuous monitoring of sleep quality in the general population. Other desirable application areas where the disclosed device provides significant benefits include high risk worker safety alarms for military / commercial pilots, astronauts, divers, firefighters, underground miners, and other workers in toxic industrial environments.
[0018] As will be appreciated by those skilled in the art, light can be described as having a wavelength and an intensity. In the visible portion of the spectrum, the wavelength of light is typically perceived by the eye as the color of the light. In the visible portion of the spectrum, the intensity of light is perceived by the eye as the brightness of the light, and in a light-based sensor instrument, as the amount of photocurrent generated by the detector. The disclosed light-based sensor can use 685 nm+ / -10 nm as a first center wavelength for detecting insufficient cellular oxygen supply. The sensor can use 850 nm+ / -10 nm as a second center wavelength used as a blank, and during insufficient cellular oxygen supply and normal cellular oxygen supply, the 685 nm+ / -10 nm signal is compared to the benchmark. The sensor can also use 850 nm+ / -10 nm as a second center wavelength for detecting excessive cellular oxygen supply by extending and reducing the detection light intensity. The sensor can detect an intensity value of light at 850 nm + / - 10 nm after the light has passed through the skin, and then subtract that value from the detected intensity value at 685 nm + / - 10 nm after the light has passed through the skin at each data acquisition cycle to produce an ECi data output value. In the following, the use of 685 nm (red) or 850 nm (infrared) indicates that these center wavelengths are included within the corresponding range of + / - 10 nm of these values.
[0019] The disclosed sensor is an energy conversion monitor (ECM). The ECi value range produced by the sensor is centered on zero when the person being tested is adapted to the oxygen supply in the atmosphere and is awake, breathing normally and resting. Once multiple (e.g., two or more) ECi values are obtained at rest, a negative trend line (less than zero) indicates that the skin receives a cellular oxygen supply that is less than the optimal value. Multiple ECi entries that produce a flat or nearly flat trend line centered on zero indicate a stable and normal state relative to the cellular oxygen supply in the skin. A positive trend (above zero) indicates that the skin may be receiving more than the required cellular oxygen supply. Sensor detection of serial changes in the detected light signal that typically occur with changes in breathing and body position can also be used to detect photonic simulations of breathing effort and body orientation during sleep.
[0020] The disclosed sensor system can be configured to also include, for example, one or more electronic accelerometer sensors for detecting (a) mechanical vibration, (b) sensor / body orientation in relation to earth gravity, and (c) body movement. Additional components of the sensor system include, but are not limited to, skin surface temperature sensors and vibrator motors for generating tactile (tactile) sensory stimulation, such as attempting to terminate an apnea event identified by the sensor system. The disclosed sensor can be configured to receive instructions and communicate via, for example, Bluetooth LE ® RF communications send data to a device, such as a smartphone, running a custom software application ("app") that is part of the disclosed sensor system.
[0021] A light-based sensor is disclosed that uses oversampling and mathematical integration to compensate for absorption of 685 nm light by skin pigment during initialization of the 685 nm light power level; thus, enabling measurement over a full range of skin pigment levels. For light to moderately pigmented skin, the power level of the 685 nm light may be incrementally increased in, for example, a 12-bit microcontroller D / A control voltage step until the average sample equals or just exceeds 85% of full scale, whereupon the successful control voltage level value is stored in the sensor memory. Recordings using an ECM have shown that a minimum of 10% light intensity detection overhead is required over a wide range of conditions and use cases, plus a 5% buffer to minimize saturation of the A / D converter; thus, an 85% target. The disclosed average sampling procedure may, for example, include obtaining a nominal number (such as 16) burst samples of light intensity during light illumination, summing the 16 detected intensity values, and then dividing the sum by the nominal number of 16 to help reduce the noise level in the signal. However, the 685 nm LED has an upper limit of sustainable power input, and experiments have found that this causes the light output to be insufficient for optimal use in deeply pigmented skin. When the upper limit of sustainable LED power input is reached, but the average sample is still less than 85% full scale, another program involving extended illumination period, oversampling and mathematical integration will be used to achieve 85% full scale detection intensity. Oversampling and mathematical integration programs are configurable so that the sum of the total number of burst samples obtained will be equal to or just exceed 85% full scale when divided by the nominal burst sample number (e.g., 16). For example, the initialization of the sensor on the deeply pigmented skin of a person may need to extend the illumination period of the 685 nm LED so that, for example, 25 burst sample values can be obtained, the sum of which just exceeds 85% full scale when divided by 16. In this exemplary case, the fully sustainable 685 nm LED power control value (e.g., 4095) and the total burst sample number 25 of the sample specified by the design are stored in the sensor memory for operation of the sensor during the current recording session. With the approach disclosed above, using burst samples in excess of the nominal number produces a desired level of signal resolution and signal overhead range, but will slightly degrade the output signal-to-noise ratio, which can be mitigated using a low noise, high gain, and sufficient bandwidth analog transimpedance amplifier for the detector signal.
[0022] The disclosed sensor can be configured to be applied to the mid-upper arm and used for monitoring during sleep. However, as will be appreciated by those skilled in the art, other application sites may include, for example, the wrist, torso, or leg. Based on experimental evidence to date, the mid-upper arm is the best location for positioning the ECM. However, other locations on the body may be used without departing from the scope of the present disclosure. There are known differences between body locations in terms of detection sensitivity, data value range, and response time for spectral light density changes to occur. For example, the same cellular hypoxia challenge causes slightly delayed but larger changes in sensor light intensity at the wrist, thigh, and calf compared to the upper arm; requiring less amplification prior to digitization. In contrast, when applied to the mid-upper back, such as, for example, for elderly people with dementia who generally cannot tolerate unfamiliar devices attached to their bodies, the ECM provides lower amplitude signal changes compared to the upper arm location; requiring slightly more signal amplification to achieve the desired resolution.
[0023] The disclosed light-based sensor identifies each subject's individual oxygen supply in relation to a central region of oxygen demand or energy conversion index (ECi) zero. When a person is healthy, resting or asleep and breathing normally, the intake of oxygen through breathing can be considered the normal minimum for that person, and can also be described as a natural balance of minimum oxygen intake and minimum oxygen demand. This condition is further described herein as an ECi zero condition; insufficient oxygen intake to meet the body's needs, or a cellular hypoxic condition, resulting in a negative ECi value trending less than zero, and more than adequate oxygen intake, or cellular hyperoxia, resulting in a positive ECi value trending greater than zero.
[0024] The disclosed light-based sensor also uses algorithmic analysis of the recorded data trends to produce a digital offset value that, when subtracted from the 850 nm data, fine-tunes the output ECi data trends relative to the individual's true ECi zero value during each usage phase. This fine-tuning offset is required for two reasons: (1) the sensor will most likely be placed on the skin when the person is not actually at that person's ECi zero point, and (2) even for 12 bits of resolution at the illumination power level, the detected intensities are unlikely to be closer to exact equality than about 20 digitized intensity level steps. In sleep testing applications, the ECi zero point is most consistently identifiable when the person wakes up after having slept for at least 3 hours. This allows a fully relaxed and awake person to breathe without airway obstruction or central apnea; therefore, systemic physiology may be allowed to reach its optimal resting level. Other applications may require performing an overall average of the ECi trends during periods of apparent minimal activity to scan for periods when the body is most likely to be in an ECi zero state; and then defining the offset value required to center the data recorded during this period of minimal activity around zero. Once so determined, the offset value is used to offset the entire recording session to be centered around the person's most likely current ECi zero point. Experimental experience indicates that the ECi zero point should not be considered to be a person's optimal state of health, but rather to establish a convenient and reproducible reference point for ECi values in a person's cellular chemical continuum. Because light absorption in the skin is due to thousands of different types of molecules within the optical path, the sensor cannot be calibrated in the usual sense to a single reference molecule, such as hemoglobin used to calibrate a pulse oximeter sensor. However, experimental evidence has demonstrated that by referencing the disclosed sensor to the relationship between the balanced minimum oxygen demand and oxygen supply conditions, which we call the ECi zero point, the continuum related to cellular oxygen supply can be effectively sensed and characterized.
[0025] Aspects of the present disclosure are directed to an energy conversion monitor (ECM) sensor. A suitable ECM sensor includes: a housing; a power source; a first light emitter positioned within an interior of the housing and configured to emit a first light at a first wavelength; a second light emitter positioned within an interior of the housing and configured to emit a second light at a second wavelength different from the first wavelength; a light detector positioned within an interior of the housing and optically isolated from the first light emitter and the second light emitter, wherein the light detector is configured to detect a resulting first tissue-interacting light signal from the first light emitter and a second tissue-interacting light signal from the second light emitter; an illumination power control circuit in communication with the first light emitter and the second light emitter, wherein the illumination power control circuit is configured to provide a computer program-defined illumination power to excite the first light emitter and the second light emitter at a corresponding computer program-defined illumination intensity; a signal amplifier in communication with the light detector; and a microcontroller configured to calculate a first output data value from the first tissue-interacting light and a second output data from the second tissue-interacting light. In some configurations, the ECM sensor uses a plurality of wavelengths of light selected by in vivo spectrometry. A plurality of wavelengths of light may be selected to maximize the corresponding change in the detected cellular light absorbance relative to at least one of the known cellular biochemical phenomena and known physiological phenomena affecting the monitored tissue. The first light emitter may have a first light emitter center wavelength value from 675 nm to 695 nm (including 675 nm and 695 nm). In addition, the microcontroller can be configured to compensate for changes in skin pigmentation levels by gradually increasing the power delivered to the first light emitter until the sustainable maximum rated power level for the first light emitter during the initialization process. If the detected intensity at 85% of the full scale cannot be detected when the sustainable maximum rated power level for the first light emitter is reached, the microcontroller can be configured to implement an oversampling and mathematical integration method. In addition, the microcontroller can be configured to increase the number of burst samples beyond the nominal number, sum all burst sample values, and divide the sum of all burst samples by the nominal number until a calculated intensity value equal to or greater than 85% of the full scale is achieved. The second light emitter may have a second light emitter center wavelength value from 840 nm to 860 nm (including 840 nm and 860 nm). The light detector may be configured to detect the first tissue-interacting light signal and the second tissue-interacting light signal at one or more timed intervals. The operation of the ECM sensor may be controlled directly by a user (i.e., by docking with the sensor), or via a software application on a mobile computing device such as a smartphone or tablet computer, which is configured to wirelessly control the ECM sensor. In other configurations, the ECM sensor may be operated via a remote computing device that communicates wirelessly with the ECM sensor (e.g., from a clinic or healthcare practitioner facility).
[0026] Another aspect of the present disclosure is directed to a system in communication with an ECM sensor. A suitable system includes: an energy conversion monitor sensor; and at least one auxiliary device, the energy conversion monitor sensor including: a housing; a power source; a first light emitter positioned within an interior of the housing and configured to emit a first light at a first wavelength; a second light emitter positioned within an interior of the housing and configured to emit a second light at a second wavelength different from the first intensity; a light detector positioned within an interior of the housing and optically isolated from the first light emitter and the second light emitter, wherein the light detector is configured to detect a resulting first tissue-interacting light signal from the first light emitter and a second tissue-interacting light signal from the second light emitter; an illumination power control circuit in communication with the first light emitter and the second light emitter, wherein the illumination power control circuit is configured to provide a computer program-defined illumination power to excite the first light emitter and the second light emitter at a corresponding computer program-defined illumination intensity; a signal amplifier in communication with the light detector; and a microcontroller configured to calculate a first output data value from the first tissue-interacting light and a second output data from the second tissue-interacting light. The auxiliary device may be selected from a second sensor, a sleep disordered breathing (SDB) treatment device, a remote computing device, and a polysomnography (PSG) system. Additionally, the system may be controlled by a software application that communicates with the ECM sensor and one or more auxiliary devices. The operation of the system may be controlled directly by a user (i.e., by docking with the sensor), or via a software application on a mobile computing device such as a smartphone or tablet computer that is configured to wirelessly control the system. In other configurations, the system may be operated via a remote computing device that wirelessly communicates with the device of the system (e.g., from a clinic or healthcare practitioner facility).
[0027] Another aspect of the present disclosure is directed to a method of using an ECM sensor. A suitable method includes the steps of applying an energy conversion monitor sensor to a skin surface of a patient; and providing power to the energy conversion monitor sensor, wherein the energy conversion monitor sensor includes: a housing; a power source; a first light emitter positioned within an interior of the housing and configured to emit a first light at a first wavelength; a second light emitter positioned within an interior of the housing and configured to emit a second light at a second wavelength different from the first wavelength; a light detector positioned within an interior of the housing and optically isolated from the first light emitter and the second light emitter, wherein the light detector is configured to detect a resulting first tissue-interacting light signal from the first light emitter and a second tissue-interacting light signal from the second light emitter; an illumination power control circuit in communication with the first light emitter and the second light emitter, wherein the illumination power control circuit is configured to provide a computer program-defined illumination power to excite the first light emitter and the second light emitter at corresponding computer program-defined illumination intensities; a signal amplifier in communication with the light detector; and a microcontroller configured to calculate a first output data value from the first tissue-interacting light and a second output data from the second tissue-interacting light. In some configurations, the method may also include the following steps: delivering a power level to the energy conversion monitor sensor so that a first detected light intensity at a first wavelength between 675 nm and 695 nm (including 675 nm and 695 nm) is equal to a second detected light intensity at a second wavelength between 840 nm and 860 nm (including 840 nm and 860 nm); determining the first detected light intensity based on the first light signal interacting with the tissue; determining the second detected light intensity based on the second light signal interacting with the tissue; comparing the first detected light intensity with a first full scale to determine a first percentage detected light intensity; comparing the second detected light intensity with a second full scale to determine a second percentage detected light intensity; and for each of the first detected light intensity and the second detected light intensity, repeating the delivering, determining, and comparing steps to obtain a detected light intensity at 85% of the full scale. In addition, the method may include: storing in memory the power level of the detected cumulative intensity of the light interacting with the tissue from the first emitter to achieve 85% full scale and the total number of burst samples added together and divided by the nominal number of burst samples; and storing in memory the power level of the detected intensity of the light interacting with the tissue from the second emitter to achieve 85% full scale. In some configurations, the method may include using the stored power level of the first emitter and the number of burst samples of the light interacting with the tissue detected from the first emitter and the stored power level of the second emitter as control parameters in data acquisition through the current recording session.In some configurations, the method may include: initializing an energy conversion monitor sensor; subtracting a detected intensity from a second light emitter after tissue interaction with a second light (between 840 nm and 860 nm, inclusive) from a detected intensity from a first light emitter after tissue interaction with a first light (between 675 nm and 695 nm, inclusive) to produce an energy conversion index (ECi) output as at least 12 bits of resolution; and generating an integer numerical analog indication of a cellular oxygen supply related chemical state. Still other configurations may include a method comprising: calculating one of a cellular oxygen supply related center and an energy conversion index zero (ECi zero) for a user; and applying an offset value to the center of the data output of the energy conversion monitor sensor output data. Still other methods may include: performing a calculation that averages low activity periods to define and record an offset value relative to zero; determining a current ECi zero point for a patient; and applying the recorded offset value to center the recorded data around the patient's current ECi zero point. In some configurations of the method, it may be advantageous that the method further comprises one or more of the following steps: in response to ECi data less than zero resulting from a decreased detection intensity at 685 nm and a concurrently stable detection intensity at 850 nm, indicating less than physiologically optimal cellular oxygen supply; in response to ECi data greater than zero resulting from a stable or increasing first detection intensity between 675 nm and 695 nm, inclusive, and a stable or decreasing second detection intensity between 840 nm and 860 nm, inclusive, indicating more than physiologically optimal cellular oxygen supply; and identifying an indication of a change in blood volume beneath the energy conversion monitor sensor, the change in blood volume caused by at least one of movement of the energy conversion monitor sensor against the skin and a change in body position relative to gravity during sleep, the change causing a series change in the first detected light intensity between 675 nm and 695 nm, inclusive, and the second detected light intensity between 840 nm and 860 nm, inclusive. Some methods further include the steps of: generating a generated signal between 840 nm and 860 nm (inclusive); and detecting the generated signal at sufficiently frequent time intervals to define the amplitude and waveform of the respiratory-induced light intensity changes as an indication of one of increased effort to breathe through a restricted or obstructed airway and decreased or absent respiratory effort from decreased or absent central nervous system respiratory drive.
[0028] Yet another aspect of the present disclosure is directed to a method for using an ECM sensor in a specific clinical scenario. For example, the method for using an ECM sensor may also include: applying an energy conversion monitor sensor to a person identified as possibly suffering from sleep disordered breathing (SDB); monitoring physiological functions related to breathing and oxygen supply during the person's sleep; and providing recorded data from the monitoring to assist in the clinical diagnosis of SDB, thereby helping to define, verify and adjust effective treatment. In another clinical method, the method may include: applying an energy conversion monitor sensor to a person with sleep disordered breathing (SDB) while using an SDB treatment device while sleeping at home; and determining the scope of management of SDB. Yet another method may include: applying an energy conversion monitor sensor to a person while using a sleep disordered breathing (SDB) treatment device while sleeping at home to provide ECi and breathing information to the SDB treatment device; controlling the SBD treatment device in response to at least one of the ECi and breathing information from the energy conversion monitor sensor; and providing monitoring of changes in the person's overall health status during sleep. Additional methods include: applying the energy conversion monitor sensor to a person identified as being at risk for developing sepsis; and detecting the possible presence of sepsis based on an ECi value that gradually tends to be less than zero. Another method also includes: applying the energy conversion monitor sensor to an infant; screening the infant for SIDS risk by recording the stability and effectiveness of breathing during sleep. Yet another method includes: applying the energy conversion monitor sensor to an infant; monitoring the stability and effectiveness of breathing during sleep; and delivering a stimulus to wake the infant from sleep during an abnormal breathing episode detected during sleep and delivering one or more of an alarm identifying the detected abnormal breathing to a caregiver. Yet another method includes: applying the energy conversion monitor sensor to a newborn infant; and providing feedback to a caregiver for adjusting the oxygen level in the breathing gas relative to the cellular oxygen demand when the infant transitions from the fetal stage to a higher level of oxygen or multiple higher levels of oxygen available from breathing air to help reduce or prevent damage related to oxygen supply. Another method includes: applying the energy conversion monitor sensor during resuscitation of a person suffering from at least one of hypoxia and asphyxia; and guiding the adjustment of oxygen in the breathing gas relative to the cellular oxygen demand of the person. Another method includes: applying an energy conversion monitor sensor to a worker in a high-risk atmospheric environment; and monitoring the worker for at least one of hypoxia and adverse effects of toxic gases in the air they breathe. Yet another method includes: applying an energy conversion monitor sensor to a pilot's forehead; and monitoring the pilot for one or more of hypoxia and g-load-induced blood flow loss to the head. Yet another method includes: applying an energy conversion monitor sensor to an athlete during and after physical exercise; assessing the athlete's physiological response; and providing recommendations for optimal performance.Another method includes: applying an energy conversion monitor sensor with dual probes to the chest and abdomen of an infant patient in intensive care; monitoring preductal cellular oxygen supply and postductal cellular oxygen supply; and detecting at least one of an anatomical abnormality of the heart, an anatomical abnormality of the great vessels, and failure of the ductus arteriosus to close properly. Yet another method includes: applying an energy conversion monitor sensor with dual probes during at least one of myocardial reperfusion during treatment of an ischemic heart attack, reperfusion of affected areas of the brain during treatment of a stroke, reperfusion of a transplanted organ, and directed oxygen resupply to ischemic tissue relative to cellular oxygen demand to help reduce or prevent reperfusion injury.
[0029] Another aspect of the present disclosure is directed to an energy conversion monitor (ECM) sensor. A suitable ECM sensor includes: a housing device; a power source device; a first light emitter device, which is positioned within the interior of the housing device and configured to emit a first light at a first wavelength; a second light emitter device, which is positioned within the interior of the housing device and configured to emit a second light at a second wavelength different from the first wavelength; a light detector device, which is positioned within the interior of the housing device and optically isolated from the first light emitter device and the second light emitter device, wherein the light detector device is configured to detect a resulting first tissue-interacting light signal from the first light emitter device and a second tissue-interacting light signal from the second light emitter device; an illumination power control circuit device, which communicates with the first light emitter device and the second light emitter device, wherein the illumination power control circuit device is configured to provide a computer program-defined illumination power to excite the first light emitter device and the second light emitter device at a corresponding computer program-defined illumination intensity; a signal amplifier device, which communicates with the light detector device; and a microcontroller device, which is configured to calculate a first output data value from the first tissue-interacting light and a second output data from the second tissue-interacting light. In some configurations, the ECM sensor uses multiple wavelengths of light selected by in vivo spectrometry. Multiple wavelengths of light may be selected to maximize the corresponding changes in the detected cellular light absorbance relative to at least one of the known cellular biochemical phenomena and known physiological phenomena that affect the monitored tissue. The first light emitter device may have a first light emitter device center wavelength value from 675 nm to 695 nm (including 675 nm and 695 nm). In addition, the microcontroller device can be configured to compensate for changes in skin pigmentation levels during the initialization process by gradually increasing the power delivered to the first light emitter device until the sustainable maximum rated power level for the first light emitter device. If the detection intensity at 85% of the full scale cannot be detected when the sustainable maximum rated power level for the first light emitter device is reached, the microcontroller device can be configured to implement oversampling and mathematical integration methods. In addition, the microcontroller device can be configured to increase the number of burst samples beyond the nominal number, sum all burst sample values, and divide the sum of all burst samples by the nominal number until a calculated intensity value equal to or greater than 85% of the full scale is reached. The second light emitter arrangement may have a second light emitter arrangement center wavelength value from 840 nm to 860 nm inclusive.The light detector arrangement may be configured to detect the first tissue-interacting light signal and the second tissue-interacting light signal at one or more timing intervals.The operation of the ECM sensor may be controlled directly by a user (i.e., by docking with the sensor), or via a software application on a mobile computing device, such as a smartphone or tablet, that is configured to wirelessly control the ECM sensor. In other configurations, the ECM sensor may be operated via a remote computing device that wirelessly communicates with the ECM sensor (e.g., from a clinic or healthcare practitioner facility).
[0030] Another aspect of the present disclosure is directed to a system in communication with an ECM sensor. A suitable system comprises: an energy conversion monitor sensor; and at least one auxiliary device, the energy conversion monitor sensor comprising: a housing device; a power source device; a first light emitter device, which is positioned within the interior of the housing device and is configured to emit a first light at a first wavelength; a second light emitter device, which is positioned within the interior of the housing device and is configured to emit a second light at a second wavelength different from the first intensity; a light detector device, which is positioned within the interior of the housing device and is optically isolated from the first light emitter device and the second light emitter device, wherein the light detector device is configured to detect a resulting first tissue-interacting light signal from the first light emitter device and a second tissue-interacting light signal from the second light emitter device; an illumination power control circuit device, which communicates with the first light emitter device and the second light emitter device, wherein the illumination power control circuit device is configured to provide a computer program-defined illumination power to excite the first light emitter device and the second light emitter device at corresponding computer program-defined illumination intensities; a signal amplifier device, which communicates with the light detector device; and a microcontroller device, which is configured to calculate a first output data value from the first tissue-interacting light and a second output data from the second tissue-interacting light. The auxiliary device may be selected from a second sensor, a sleep disordered breathing (SDB) treatment device, a remote computing device, and a polysomnography (PSG) system. Additionally, the system may be controlled by a software application that communicates with the ECM sensor and one or more auxiliary devices. The operation of the system may be controlled directly by a user (i.e., by docking with the sensor), or via a software application on a mobile computing device such as a smartphone or tablet computer that is configured to wirelessly control the system. In other configurations, the system may be operated via a remote computing device that wirelessly communicates with the device of the system (e.g., from a clinic or healthcare practitioner facility).
[0031] Another aspect of the present disclosure is directed to a method of using an ECM sensor. A suitable method includes the steps of applying an energy conversion monitor sensor to a skin surface of a patient; and providing power to the energy conversion monitor sensor, wherein the energy conversion monitor sensor includes: a housing device; a power source device; a first light emitter device, which is positioned within the interior of the housing device and configured to emit a first light at a first wavelength; a second light emitter device, which is positioned within the interior of the housing device and configured to emit a second light at a second wavelength different from the first wavelength; a light detector device, which is positioned within the interior of the housing device and optically isolated from the first light emitter device and the second light emitter device, wherein the light detector device is configured to detect light from the first light. a first tissue-interacting light signal from the emitter device and a second tissue-interacting light signal from the second light emitter device; an illumination power control circuit device that communicates with the first light emitter device and the second light emitter device, wherein the illumination power control circuit device is configured to provide an illumination power defined by a computer program to excite the first light emitter device and the second light emitter device at a corresponding illumination intensity defined by the computer program; a signal amplifier device that communicates with the light detector device; and a microcontroller device that is configured to calculate a first output data value from the first tissue-interacting light and a second output data from the second tissue-interacting light. In some configurations, the method may also include the following steps: delivering a power level to the energy conversion monitor sensor so that a first detected light intensity at a first wavelength between 675 nm and 695 nm (including 675 nm and 695 nm) is equal to a second detected light intensity at a second wavelength between 840 nm and 860 nm (including 840 nm and 860 nm); determining the first detected light intensity based on the first optical signal interacting with the tissue; determining the second detected light intensity based on the second optical signal interacting with the tissue; comparing the first detected light intensity with a first full scale to determine a first percentage detected light intensity; comparing the second detected light intensity with a second full scale to determine a second percentage detected light intensity; and for each of the first detected light intensity and the second detected light intensity, repeating the delivering, determining, and comparing steps to obtain a detected light intensity at 85% of the full scale. In addition, the method may include: storing in a memory the power level of the detected cumulative intensity of light interacting with tissue from the first emitter to achieve 85% full scale and the total number of burst samples added together and divided by the nominal number of burst samples; and storing in a memory the power level of the detected intensity of light interacting with tissue from the second emitter to achieve 85% full scale.In some configurations, the method may include using a stored power level of a first emitter and a number of burst samples of light detected from the first emitter interacting with tissue and a stored power level of a second emitter as control parameters in data acquisition through a current recording session. In some configurations, the method may include: initializing an energy conversion monitor sensor; subtracting a detected intensity from the second light emitter device after tissue interaction with the second light (between 840 nm and 860 nm, inclusive) from a detected intensity from the first light emitter device after tissue interaction with the first light (between 675 nm and 695 nm, inclusive) to produce an energy conversion index (ECi) output as at least 12 bits of resolution; and generating an integer numerical analog indication of a cellular oxygen supply related chemical state. Still other configurations may include a method comprising: calculating one of a cellular oxygen supply related center and an energy conversion index zero (ECi zero) for a user; and applying an offset value to the center of the data output of the energy conversion monitor sensor output data. Still other methods may include: performing a calculation averaging the low activity periods to define and record an offset value relative to zero; determining a current ECi zero point for the patient; and applying the recorded offset value to center the recorded data about the patient's current ECi zero point. In some configurations of the method, it may be advantageous that the method further comprises one or more of the following steps: in response to ECi data less than zero resulting from a decreased detection intensity at 685 nm and a concurrently stable detection intensity at 850 nm, indicating less than physiologically optimal cellular oxygen supply; in response to ECi data greater than zero resulting from a stable or increasing first detection intensity between 675 nm and 695 nm, inclusive, and a stable or decreasing second detection intensity between 840 nm and 860 nm, inclusive, indicating more than physiologically optimal cellular oxygen supply; and identifying an indication of a change in blood volume beneath the energy conversion monitor sensor, the change in blood volume caused by at least one of movement of the energy conversion monitor sensor against the skin and a change in body position relative to gravity during sleep, the change causing a series change in the first detected light intensity between 675 nm and 695 nm, inclusive, and the second detected light intensity between 840 nm and 860 nm, inclusive.Some methods further include the steps of: generating a generated signal between 840 nm and 860 nm (inclusive); and detecting the generated signal at sufficiently frequent time intervals to define the amplitude and waveform of the respiratory-induced light intensity changes as an indication of one of increased effort to breathe through a restricted or obstructed airway and decreased or absent respiratory effort from decreased or absent central nervous system respiratory drive.
[0032] Yet another aspect of the present disclosure is directed to a method for using an ECM sensor in a specific clinical scenario. For example, the method for using an ECM sensor may also include: applying an energy conversion monitor sensor to a person identified as possibly suffering from sleep disordered breathing (SDB); monitoring physiological functions related to breathing and oxygen supply during the person's sleep; and providing recorded data from the monitoring to assist in the clinical diagnosis of SDB, thereby helping to define, verify and adjust effective treatment. In another clinical method, the method may include: applying an energy conversion monitor sensor to a person with sleep disordered breathing (SDB) while using an SDB treatment device while sleeping at home; and determining the scope of management of SDB. Yet another method may include: applying an energy conversion monitor sensor to a person while using a sleep disordered breathing (SDB) treatment device while sleeping at home to provide ECi and breathing information to the SDB treatment device; controlling the SBD treatment device in response to at least one of the ECi and breathing information from the energy conversion monitor sensor; and providing monitoring of changes in the person's overall health status during sleep. Additional methods include: applying the energy conversion monitor sensor to a person identified as being at risk for developing sepsis; and detecting the possible presence of sepsis based on an ECi value that gradually tends to be less than zero. Another method also includes: applying the energy conversion monitor sensor to an infant; screening the infant for SIDS risk by recording the stability and effectiveness of breathing during sleep. Yet another method includes: applying the energy conversion monitor sensor to an infant; monitoring the stability and effectiveness of breathing during sleep; and delivering a stimulus to wake the infant from sleep and delivering one or more of an alarm identifying the detected abnormal breathing to a caregiver during an episode of abnormal breathing detected during sleep. Yet another method includes: applying the energy conversion monitor sensor to a newborn infant; and providing feedback to a caregiver for adjusting the oxygen level in the breathing gas relative to the cellular oxygen demand when the infant transitions from the fetal stage to a higher level of oxygen or multiple higher levels of oxygen available from breathing air to help reduce or prevent damage related to oxygen supply. Another method includes: applying the energy conversion monitor sensor during resuscitation of a person suffering from at least one of hypoxia and asphyxia; and guiding the adjustment of oxygen in the breathing gas relative to the cellular oxygen demand of the person. Another method includes: applying an energy conversion monitor sensor to a worker in a high-risk atmospheric environment; and monitoring the worker for at least one of hypoxia and adverse effects of toxic gases in the air they breathe. Yet another method includes: applying an energy conversion monitor sensor to a pilot's forehead; and monitoring the pilot for one or more of hypoxia and g-load-induced blood flow loss to the head. Yet another method includes: applying an energy conversion monitor sensor to an athlete during and after physical exercise; assessing the athlete's physiological response; and providing recommendations for optimal performance.Another method includes: applying an energy conversion monitor sensor with dual probes to the chest and abdomen of an infant patient in intensive care; monitoring preductal cellular oxygen supply and postductal cellular oxygen supply; and detecting at least one of an anatomical abnormality of the heart, an anatomical abnormality of the great vessels, and failure of the ductus arteriosus to close properly. Yet another method includes: applying an energy conversion monitor sensor with dual probes during at least one of myocardial reperfusion during treatment of an ischemic heart attack, reperfusion of affected areas of the brain during treatment of a stroke, reperfusion of a transplanted organ, and directed oxygen resupply to ischemic tissue relative to cellular oxygen demand to help reduce or prevent reperfusion injury.
[0033] Join by reference
[0034] All publications, patents, and patent applications mentioned in this specification are incorporated herein by reference, as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. References include, for example:
[0035] US 2006 / 0009685 A1 to Finarov et al., published on January 12, 2006, entitled “Device and Method for Non-Invasive Optical Measurements”;
[0036] US 2008 / 0081966 A1 to Debreczeny, published on April 3, 2008, entitled “SymmetricLED Array for Pulse Oximetry”;
[0037] US 2008 / 0208009 A1 to Shklarski, published on August 28, 2008, entitled “Wearable Device, System and Method for Measuring Vital Parameters”;
[0038] US 2010 / 0324390 A1 to McLaughlin, published on December 23, 2010, entitled “Measurement of Oxygen Saturation of Blood Haemoglobin”;
[0039] US 2011 / 0054336 A1 to Jornod, published on March 3, 2011, entitled “Method and Device for Measuring the Pulse by Means of Light Waves with Two Wavelengths”;
[0040] US 2013 / 0303921 A1 to Chu, published on November 14, 2013, entitled “System and Method for Measurement of Physiological Data with Light Modulation”;
[0041] US 2013 / 0317331 A1, issued to Bechtel on November 28, 2013, entitled “MonteCarlo and Iterative Methods for Determination of Tissue Oxygen Saturation”;
[0042] US 2014 / 0275888 A1 to Wegerich, published on September 18, 2014, entitled “Wearable Wireless Multisensor Health Monitor with Heat Photoplethysmograph”;
[0043] US 2015 / 0011854 A1, “Continuous Transdermal for “Signal Monitoring System and Method; Including EMI-Shielding Coupler”” to Frix, published on January 8, 2015, CAS Medical Systems;
[0044] US 2015 / 0057511 A1 to Basu, published on February 26, 2015, entitled “Sensor and Method for Continuous Health Monitoring”;
[0045] US 2017 / 0049336 A1 to Hatch, published on February 23, 2017, entitled “Physiological Sensors, Systems, Kits and Methods Therefor”;
[0046] US 2017 / 0112422 A1 to Hatch, published on April 27, 2017, entitled “Optical Physiologic Sensors and Methods”; and
[0047] US 5830137 A issued on November 3, 1998 to Scharf for “Green Light Pulse Oximeter”;
[0048] US 6801799 B2, issued on October 5, 2004 to Mendelson, entitled “Pulse Oximeter and Method of Operation”;
[0049] US 7,691,067 B2, issued on April 6, 2010 to Westbrook, entitled “Method for Measuring Central Venous Pressure or Respiratory Effort”;
[0050] US 7738935 B1, issued on June 15, 2010 to Turcott, entitled “Methods and Devices for Reduction of Motion-Induced Noise in Pulse Oximetry”;
[0051] US 8,073,516 B2, issued December 6, 2011 to Scharf, entitled “Separating Motion from Cardiac Signals Using Second Order Derivative of the Photo-Plethysmogram and Fast Fourier Transforms”;
[0052] US 8,133,176 B2, issued on March 13, 2012 to Porges, entitled “Method and Circuit for Indicating Quality and Accuracy of Physiological Measurements”;
[0053] US 8346327 B2, issued on January 1, 2013 to Campbell, entitled “Method for Identification of Sensor Site by Local Skin Spectrum Data”;
[0054] US 9125563 B2, entitled “Signal Monitoring System Including EMI-Shielding Coupler”, CAS Medical Systems, September 8, 2015;
[0055] US 9357954 B2, issued on June 7, 2016, entitled “Simultaneous Measurement of Pulse and Regional Blood Oxygen Saturation”, Covidien LP;
[0056] US 10327710 B2, issued on June 25, 2019, for “Age Calibration for Tissue Oximetry” to Nonin Medical;
[0057] US 10335072 B2, issued on July 2, 2019, entitled “Physiologic Monitor,” Masimo Corporation;
[0058] US 10369310 B2, issued on August 6, 2019, entitled “Method and Apparatus for Treatment of Respiratory Disorders”, ResMed Limited;
[0059] US 10376670 B2, issued on August 13, 2019, entitled “Methods and Systems for Sleep Management,” ResMed Sensor Technologies;
[0060] US 10383569 B2, issued on August 20, 2019, for “Mechanical Ventilation in the Presence of Sleep Disordered Breathing,” ResMed Limited;
[0061] WO 2015 / 168235 A1 to Hatch, published on November 5, 2015, entitled “Physiological Sensors, Systems, Kits and Methods Therefor”;
[0062] Cornet AD et al., "The potential harm of oxygen therapy in medical emergencies", Critical Care 2013, 17:313, PMID: 23635028;
[0063] Hashimoto I et al., "The features of thrombus in a microvessel injury model and the antithrombotic efficacy of heparin, urokinase, and prostaglandin E1", Plastic and Reconstructive Surgery, June 2003, 2307-2314;
[0064] Hunt C et al., "Cardiorespiratory events detected by home memory monitoring and one-year neurodevelopmental outcome", J Pediatr 2004; l45:465-71, PMID: 15480368;
[0065] Hyttel-Sorensen S et al., "Peripheral tissue oximetry: comparing three commercial near-infrared spectroscopy oximeters on the forearm", J Clin Monit Comput (2014) 28:149-155, PMID: 23990288;
[0066] Joosen SA et al., "Dynamic loop gain increases upon adopting the supine body position during sleep in patients with obstructive sleep apnea", Respirology November 2017; 22(8): 1662-1669, PMID: 28730724;
[0067] Kalogeris T et al., "Ischemia / Reperfusion", Comprehensive Physiology 7:113-170, 2017, PMID: 28135002;
[0068] Liegl R et al., "Retinopathy of prematurity: the need for prevention", Eye and Brain 2016:8 91-102, PMID: 28539604;
[0069] Lopez S, "Pulse Oximeter Fundamentals and Design", Document Number: AN4327, Rev.2, 11 / 20 / 12, Freescale Semiconductor Application Note;
[0070] Mayevsky A et al., "Mitochondrial function and tissue vitality: bench-to-bedside real-time optical monitoring system", J Biomedical Optics, 16(6), 067004, June 2017, PMID: 21721825;
[0071] Miller et al., "Antenatal antioxidant treatment with melatonin todecrease newborn neurodevelopmental deficits and brain injury caused by fetalgrowth restriction", J Pineal Res 2014 April: 56(3): 283-94, PMID: 24456220;
[0072] Okuno et al., "Rotation and structure of Fo and F1-ATP synthase", J.Biochem.2011;149(6):655-664, PMID: 21524994;
[0073] Ramanathan R et al., "Cardiorespiratory events recorded on home monitors: comparison of healthy infants with those at increased risk for SIDS", JAMA, May 2, 2001, Volume 285, Issue 17, 2199-2207, PMID: 15480368;
[0074] Rolfe P, "In vivo near-infrared spectroscopy", Annu.Rev. Biomed.Eng.2000 02:715-54, PMID: 11701529; and
[0075] Rozova EV et al., “Structural and dynamic changes in mitochondria of rat myocardium under acute hypoxic hypoxia: role of mitochondrial ATP-dependent potassium channel”, Biochemistry (Moscow) 2015, Vol. 89, No. 8, pp. 994-1000, PMID: 26547067. BRIEF DESCRIPTION OF THE DRAWINGS
[0076] The novel features of the present invention are particularly set forth in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by referring to the following detailed description and the accompanying drawings, which set forth illustrative embodiments in which the principles of the present invention are utilized, wherein:
[0077] Figures 1A to 1D An exemplary sensor device is illustrated;
[0078] Figure 2 is an exemplary schematic architecture for a sensor monitoring device system;
[0079] Figure 3 is an exemplary operational flow chart for sensor monitoring device system firmware;
[0080] Figure 4 An exemplary data collection flow chart is illustrated;
[0081] Figure 5 illustrates an exemplary LED power level initialization flow chart;
[0082] Fig. 6A is the energy conversion index (ECi) graph recorded during normal sleep;
[0083] Figure 6B A raw data graph of intensity over time recorded during normal sleep is illustrated;
[0084] Figure 6C The figure shows the recorded Figure 6B A selected portion of the extracted intensity variation over time;
[0085] FIG. 7A to FIG. 7B is a graph of abnormal ECi and raw data recorded during sleep, showing the response to an OSA episode;
[0086] Figure 7C Is from Figure 7B The time extension of the original data segment B;
[0087] Fig. 8A The diagram shows 7A to 7C but select two different nested segments C and D for the time-expanded view; Figure 8B Is from Fig. 8A The original data graph of ECi recorded in;
[0088] Figure 8C Is from Fig. 8A The time-extended segment C of the ECi record in;
[0089] Fig.8D Is from Figure 8C The raw data graph of fragment C of ; and Fig. 8E Is from Fig.8D The original data graph of fragment D;
[0090] Figure 9A to Fig.9E A sleep recording segment is illustrated showing when and in which direction ECi data can be used to trigger an APAP change in airway pressure;
[0091] FIG. 10A to FIG. 10D is a graph reflecting exemplary output data and signal trends for a sensor monitoring device;
[0092] Figure 11A to Fig. 11B illustrates an exemplary graph of ischemia / reperfusion spectral absorption test results obtained from a spectrometer recording;
[0093] Figure 12A to Fig. 12B illustrates an exemplary graph of changes in skin spectral absorbance just before and after blood return, obtained from a spectrometer recording;
[0094] Figure 13A to Fig.13D illustrates an exemplary graph of an exercise recording of ECi, raw data, heart rate, and SpO2 trends acquired from a sensor monitoring device;
[0095] Figure 14A to Fig. 14B illustrates an exemplary graph of a recording acquired from a sensor monitoring device during normal sleep breathing;
[0096] Figure 15A to Fig. 15B illustrates an exemplary graph of a recording acquired from a sensor monitoring device during sleep disordered breathing;
[0097] Figure 15C to Fig.15D Figures 15A to 15B illustrate data acquired from a sensor monitoring device during restricted and periodic breathing. Fig. 15B An exemplary diagram of a fragment of;
[0098] Figure 16A to Fig. 16B illustrates exemplary recordings obtained from a sensor monitoring device during sleep disordered breathing, obstructive and central apnea; and
[0099] FIG. 17A to FIG. 17B An exemplary dual-probe sensor is illustrated. DETAILED DESCRIPTION
[0100] Figure 1A1. An ECM sensor 100 is depicted in FIG. An outer surface 108 of a sensor aperture member 107 contacts the patient's skin. A light emitter aperture opening 110 and a light detector aperture opening 112 are provided, which may be filled with a transparent plastic sealant to present a flat surface to the patient's skin when applied. A plastic resin encapsulation 114 housing hermetically encapsulates and mechanically protects the internal components of the ECM sensor 100 device.
[0101] Figure 1B Shows Figure 1A 100. As shown, the sensor aperture member 107 has a length, a height, and a width, and is adhered to the end of the flexible circuit 116. The component volume space for the surface mount technology (SMT) component is shown, which is mounted on the main printed circuit board (PCB) portion of the main circuit 118. The flexible circuit 116 can be configured to be folded over the SMT component. Additional electronic components (such as Bluetooth LE ® A transceiver 120 and optionally a vibrator motor for tactile stimulation) may also be mounted to the main circuit 118.
[0102] Figure 1C The sensor aperture member 107 is shown removed from above the light emitting diodes (LEDs) 124 and 126 and the detector 128 (such as a photodiode detector). The inner surface 109 of the sensor aperture member 107 is shown. The sensor aperture member 107 has at least one inner wall 122, which provides an optical barrier between the first chamber 140 and the second chamber 142 when fixed to the flexible circuit 116. The first chamber 140 (light emitter cavity) and the second chamber 142 (detector cavity) define a three-dimensional (3D) recess on the inner surface 109 of the sensor aperture member 107. The use of metal for the sensor aperture member 107 can be used in one configuration. However, as will be appreciated by those skilled in the art, plastic materials that are sufficiently opaque to both red light and infrared light can also be used to form the sensor aperture member 107, including the inner wall light barrier. In addition, the sensor aperture member 107 can be attachable (e.g., using a suitable adhesive such as epoxy).
[0103] A red LED 124, an infrared LED 126, and a detector 128 such as a silicon photodiode can be mounted on the flexible circuit 116. LED power control and signal amplifier components are mounted on the underside of the sensor portion of the flexible circuit 116. The flexure 130 of the flexible circuit 116 carries circuit traces from the sensor to the main circuit 132.
[0104] As will be appreciated by those skilled in the art, the actual layout may take a variety of forms without departing from the scope of the present disclosure. In some configurations, the lead pattern of the microcontroller may have a pattern that radiates in multiple directions. Thus, if the LED and sensor are placed in the middle, the microcontroller leads will need to be directed around the LED and sensor. As illustrated, by placing the optical component on the flexible circuit, a simplified layout is achieved. However, in some configurations, the Bluetooth transceiver may have an associated microcontroller that is capable of performing optical component control, which would allow for a centrally located sensor.
[0105] Figure 1D The underside of the main circuit 132 is illustrated, with the battery 134 and battery recharging coil 136 located thereon, and the flexure 130 and optical member portion of the flexible circuit 116 bent around the end of the main circuit 132 .
[0106] Figure 2 2 is a schematic block diagram of an ECM sensor 200 on the skin of a test subject, including an ECM sensor system 202 and a computer-implemented software application ("app") 206 operating on a smartphone 204. Sensor control command and data transfer 208 between the ECM sensor system 202 and the smartphone 204 is managed via an RF transceiver 210 in the ECM sensor system 202 and a Bluetooth LE® RF transceiver and app 206 operating in an iPhone® or Android® operating system smartphone or equivalent. The light emitting electro-optical components of the sensor system are enclosed within a metal or plastic sensor aperture component 107 that is opaque to visible and infrared light and is housed within the sensor aperture component 107. Figure 1C The first chamber 140 contains the red LED 124 and the infrared LED 126. The red LED 124 and the infrared LED 126 can be further packaged together in a transparent plastic; thus, the light from the LED passes through Figure 1A The light emitter aperture opening 110 provides a path for emission.
[0107] The sensor aperture member 107 has a second chamber 142 that houses a detector 128, such as a silicon photodiode, and may also be filled with an optically clear plastic. The housing of the sensor aperture member 107 has an inner wall 122 positioned between the first chamber 140 and the second chamber 142, which separates the two chambers and blocks light from the red LED 124 and the infrared LED 126 from being transmitted to the interior of the detector 128. Therefore, any light detected by the detector 128 occurs after the light has been transmitted through the skin.
[0108] When in use, the ECM sensor system 202 is placed on the patient's skin 224. The emitted light 226 and 228 passes through the epidermis and dermis 230 of the skin, but does not functionally penetrate the superficial fascia or underlying muscle 234.
[0109] Top-level operational commands are transmitted from the ECM sensor system 202 via data transfer 208, such as from an application 206 such as a smartphone application utilizing Bluetooth LE. ® The sensor microcontroller 240 uses the application 206 to establish an RF link procedure and then performs a sensor initialization procedure to establish the optimal power level delivered to the LED. Upon completion of the initialization process, the sensor microcontroller 240 performs a data acquisition cycle at a time interval set by the application 206, which is 1 Hz for the 685 nm and 850 nm LEDs for ECi monitoring, plus additional illumination of only the 850 nm LED for monitoring respiration (up to 10 Hz total). During each ECi data acquisition cycle, detection light measurements of ambient light (i.e., not illuminated by any of the LEDs), red LED illumination, and infrared LED illumination are taken and stored in the sensor memory 214. The current data is then transmitted as raw data to the application 206 via a data transfer 208 (such as an RF transceiver link) for recording, display, and analysis.
[0110] The LED power amplifier 220 receives the D / A analog control voltage from the sensor microcontroller 240. The LED power amplifier 220 then sends a corresponding current level to the red LED 124 and / or the infrared LED 126. The detector 128 communicates with the signal amplifier 242, which communicates with the sensor microcontroller 240. The sensor microcontroller 240 also communicates with the sensor memory 214 and the RF transceiver 210.
[0111] In another configuration, the ECM sensor 200 communicates directly or indirectly with an airway therapy device, such as an APAP machine or a CPAP machine. Data from the ECM sensor 200 provided directly or indirectly to the airway therapy device may be processed by the airway therapy device to cause a change in the airway therapy (e.g., air pressure) being administered. Direct submission of data may be wired or wireless. Indirect submission of data may be via an auxiliary device, such as a smartphone, or via a remote central station that processes the data received from the ECM sensor and then transmits the processed data or machine operation commands to the airway therapy device.
[0112] Figure 3is a block diagram illustrating a patient experience of an ECM sensor 100 for the purpose of monitoring during sleep. A recharged ECM sensor 100 is first applied 302 to a patient. Suitable locations for application of the device include the mid-upper arm with an elastic wrap so that the sensor is held comfortably but securely in place without restricting blood flow in the arm. The mid-upper arm position is a suitable location for sleep monitoring. However, as will be appreciated by those skilled in the art, other locations on the body may be employed without departing from the scope of the present disclosure, including but not limited to the forehead, wrist, body core, thigh, or calf.
[0113] The application 206 is then loaded and opened 304 by the patient using an automatic RF link 306 between the smartphone and the ECM sensor 100. After receiving a sensor initialization command 308, for example, from the smartphone application and the sensor responding that the sensor is initialized 310, the ECM sensor 100 is initialized. The initialization command is an automatic link-finding process whereby the sensor's RF link confirmation response is automatically detected and indicated on the application graphical user interface (GUI) presented in the smartphone. The patient can select application settings 312 for the recording session on the application 206, and then the patient can choose to start recording data immediately 316, or wait 314 until a selected moment, such as when it is desired to synchronize the sleep recording with the recording of another sensor system. When the start of recording data 316 is indicated, an instruction is sent to the ECM sensor 100 to start data acquisition 318 at a selected cycle frequency (such as once per second for a 685 nm LED and up to 10 times per second for an 850 nm LED in an application for an infant who may have a respiratory rate of more than 100 times per minute during sleep). When data is collected and transmitted 320 to the smartphone via the RF link, the data is recorded in the smartphone memory and, optionally, displayed graphically on the smartphone GUI screen for the application 206 as raw data and energy conversion index (ECi) trends. When the patient commands to stop recording 322, the application 206 generates a stop command 324, which is transmitted to the ECM sensor 100 via the RF link to stop data collection. The recorded data is saved in the smartphone memory in a desired computer format (such as tab-delimited ASCII text (*.txt)), and the data file can then be transmitted through a variety of digital communication processes available with smartphones. The patient then removes the sensor 326 and charges the ECM sensor 100 328 by, for example, placing the ECM sensor 100 on a compatible recharging pad to wirelessly charge the internal battery. When the battery of the ECM sensor is fully charged again, the ECM sensor can be used again. In some configurations, the system can be configured to automatically start and stop recording based on previously implemented instructions. Thus, for example, the system may be programmed to collect data between specific time periods or when specified events occur (eg, the onset of snoring, movement of the patient during sleep, etc.).
[0114] As will be appreciated by those skilled in the art, in some configurations, the ECM sensor 100 may be automatically or semi-automatically operated via an airway therapy device or a central server in communication with the airway therapy device and the ECM sensor 100. In these configurations, use of a smartphone may not be required. Thus, a system according to the present disclosure may include two or more of the following: an ECM sensor, a smartphone, an airway therapy device, and / or a central server.
[0115] Figure 4 4 is a flow chart 400 depicting the operation of the ECM sensor 100. The use procedure for monitoring sleep begins with placing the sensor on the skin (first application 302). As previously noted, the ECM sensor can be placed on the upper mid-arm using an elastic wrap or armband. The application 206 can be used to send a sensor initialization command 308 to the ECM sensor, thereby generating an optimal D / A control voltage level for the red LED 402 and an optimal D / A control voltage level for the infrared LED 424. The data acquisition cycle includes emitting red LED light 404 and detecting diffuse red LED light 406 to determine a red intensity value 408. The data acquisition cycle includes emitting infrared LED 414 and detecting diffuse infrared light 416 to determine an infrared intensity value 418. The process can also include periodically sampling a background ambient light value, which is subtracted from the detected diffuse red LED light 406 and the detected diffuse infrared light 416. The resulting infrared intensity value 418 is subtracted 420 from the resulting red intensity value 408, with the background value removed, to produce an ECi value 422. ECi values can range from less than -400 (deeply hypoxic skin) through zero (normally aerobic skin) to over +500 (very highly oxygenated skin). The red intensity value 408, infrared intensity value 418, and ECi value 422 are then stored in the sensor memory 410. The data can then be transmitted to the application via RF transmission. This data acquisition loop repeats 412 until the patient indicates that data acquisition is to stop (i.e., stops recording 322), causing the data acquisition loop repeat 412 to return "no" and the sensor operation ends 426.
[0116] Figure 5 is based on Figure 3 Flowchart 500 of the sensor initialization process for the sensor initialization command 308 in FIG. 1. The sensor initialization command 308 begins by setting the red LED power level at 30% of the full scale of the LED power D / A converter 502. The resolution is a minimum of 12 bits (i.e., 0-4095). The D / A voltage is then amplified 504 and power is provided to the red LED to project red LED light 506. The detected intensity 508 of the projected red LED light after it has been diffused through the skin is determined by Figure 1C The detector 128 (e.g., a photodiode) in the Figure 2 The signal is amplified by the amplifier 242 and then sent to Figure 2The diffuse red light is sampled and digitized, and the digital value is checked to see if it is equal to or greater than 85% full scale 510 of the output data A / D converter. The resolution for the output data is at least 12 bits (e.g., 0-4095). If the digitized value is less than 85% full scale (e.g., <3480), the red LED D / A voltage is incremented by 12 bits at step 512, amplified 504, and red LED light is again projected 506 into the skin. This loop continues until the digitized data equals or exceeds 85% full scale, at which point the optimal red LED D / A voltage level 402 is stored in Figure 2 514. However, if the upper limit of the 12-bit D / A red LED voltage range is reached without achieving 85% full-scale data 514, such as occurs with dark pigmented skin, then a sample integration process 516 is entered. The sampling process involves taking 16 burst samples while the red LED is illuminated, summing their digital values, and dividing the sum by 16 to produce an average sample. Using integration 516, the number of burst samples is incremented at each cycle until the sum of the digital values divided by 16 equals or exceeds 85% full-scale 510.
[0117] When 85% full scale 510 is achieved, the optimal red LED D / A voltage level 402 and the number of burst samples 532 are stored in the sensor memory 534. Upon completion of the red LED initialization, the infrared LED D / A voltage is similarly cycled, starting with a 30% full scale infrared LED D / A voltage 522, to illuminate the skin 224 (by projecting 524 infrared LED light onto the skin). Figure 2 ), the signal is sampled and digitized 526, and checked for equal to or greater than 85% full scale 12-bit resolution 528. Since infrared wavelengths are not absorbed by skin pigments, and the efficiency of power input to light output for infrared LEDs is much greater than for red LEDs, the infrared LED D / A voltage is easily achieved without integration. When equal to or greater than 85% full scale output data value 528 is achieved, the optimal infrared LED D / A voltage 424 is stored in the sensor memory. When both the optimal red LED D / A voltage level 402 and the optimal infrared LED D / A voltage level value 424 are then stored in the sensor memory 534, the sensor initialization process is complete.
[0118] The importance of identifying weak or absent respiratory effort during sleep ensures that the best resolution is obtained. To achieve this, Figure 8BThe cascade drop in intensity values that typically occurs during the initial hour 802 of sleep needs to be compensated for so that the baseline detection intensity rises back up to 85% full scale range during the remainder of the night's sleep. This is done by repeating the sensor initialization step at 30 minutes and then again one hour into the sleep recording. Figure 4 During the short period of time of the sensor initialization command 308 in the Figure 2 The sensor memory 214 in the 2000A sends full-scale red (e.g., 4095) and infrared (e.g., 4095) data values. This produces full-scale "expected artifact" spikes in the output red and infrared intensity raw data and zero ECi values, indicating the expected deviation in data values during repeated initialization; and then, Figure 2 The ECM sensor system 202 in continues to sample and record the detected data using the new initialized LED power control and burst sample number values for subsequent cycles.
[0119] Using Bluetooth LE® for the RF link has the advantage of automatically attempting to retransmit data for which a full acknowledgement of receipt has not been received. However, in the event of an extended period of interruption of RF communications, when the RF link is restored, Figure 2 The sensor memory 214 in has the capability to store up to 4 hours of data for transmission.
[0120] Fig. 6A is a graph of ECi recorded during normal sleep. ECi values during sleep have been recorded in the range between -450 and 100. The X-axis on the ECi graph is shown in one hour time intervals 602 corresponding to one hour of recording. Fig. 6A is a 7-hour "sleep" segment of a longer recording that begins with the subject lying in his easy chair watching TV before going to bed. The calculated ECi values vary very little; never dropping below -50, indicating that he had normal breathing and skin oxygen supply throughout the night.
[0121] Figure 6B It is used to calculate Fig. 6A A raw data graph of ECi trend data in FIG. 6 shows an infrared signal strength trace 610 and a red signal strength trace 612. A brief period of mild respiratory disturbance A is selected. Figure 6C The relatively consistent raw data trace indicates minimal changes in body position or tossing during sleep. Although indications of breathing changes cannot be completely ruled out, this is one of the "most normal" sleep recordings ever made.
[0122] Figure 6C Recorded during normal sleep Figure 6B 604. The time expansion of the fragment A of the raw data graph. The Y axis reflects the detection signal intensity, and the X axis reflects the time interval 604 of one minute. Normal quiet breathing 614 is shown at the beginning and end of the raw data fragment. Several slightly obstructed breaths 616 (such as slight snoring) lead to a period of reduced breathing effort 618 of almost one minute, which causes a slight decline in both the red signal intensity trace 612 and the infrared signal intensity trace 610, but the decline of the red signal intensity trace 612 is more, thereby giving an indication that the oxygen supply to the skin is slightly reduced. In addition, it is worth noting that several places through the middle part of the figure are series changes of both the red signal intensity trace 612 and the infrared signal intensity trace 610. The more obvious change is due to the deeper shift of the intrathoracic pressure required to move air through the partially obstructed airway. If the airway is completely blocked in a single breath, there is typically a series vertical spike 620 from the effort of the short increase.
[0123] Fig. 7A is a graph of abnormal ECi trends recorded during sleep with obstructive sleep apnea (OSA), snoring, and central sleep apnea (CSA). The Y-axis is the ECi value, and the X-axis is time (hours). The X-axis uses the same Fig. 6A The same one-hour time interval 602 is used for the X-axis in FIG. Fig. 6A Same Y-axis range as in . Figure 7B Segment B, which occurs at approximately the 1 hour mark in Figure 7C Time expansion is performed in .
[0124] Figure 7B Is from Fig. 7A The original data graph of . Note that for Fig. 7A The negative index value of the ECi shift in the depth corresponds to when FIG. 6B to FIG. 6C The red signal intensity trace 612 shown in FIG is a period when the trace is of a lower value than the infrared signal intensity trace 610, indicating more red light absorption in the skin. The figure illustrates both the red signal intensity trace 612 and the infrared signal intensity trace 610. The framed segment B is at Figure 7C is expanded by time.
[0125] Figure 7C yes Figure 7B The time expansion of the raw data segment B in FIG. 1 also shows both the red signal strength trace 612 and the infrared signal strength trace 610. Figure 6C, the X-axis is the time value at one minute time interval 604. The segment begins with 2 minutes of slight snoring and periodic breathing, resulting in a slight periodic decrease in red intensity relative to infrared intensity, indicating a cellular hypoxic response. Then, there is a one-minute episode of severe airway restriction 712, accompanied by three strong attempts to obtain a breath. This is followed by a one-minute period of obvious central sleep apnea 714 (i.e., no breathing effort), but the increased effort to obtain breathing through the restricted airway is restored, which occurs together with obstructive apnea 716. This airway restriction / obstruction period is followed by another period of central apnea 718 with minimal respiratory movement, which ends with a respiratory obstruction 720. Finally, the subject is clearly awakened from sleep, enough to open his airway and resume normal breathing 722 when he attempts to return to sleep.
[0126] Fig. 8A is with Fig. 7A The same ECi recording with two segments selected for time-expanded viewing: C and D. Segment D is a subset of segment C and occurs between hours 2 and 3. Segment E is an example of a subject turning over. The Y-axis is the ECi index value and the X-axis is the time value at a one-hour time interval 602.
[0127] Figure 8B Is from Fig. 8A Graph of raw data from an ECi recording in , showing two nested segments for viewing together with both the red signal intensity trace 612 and the infrared signal intensity trace 610. The X-axis is the time value at the one hour time interval 602. The Y-axis is the detected signal intensity. In addition, note the tandem downward trend during the initial hour 802. This baseline drop of almost 500 counts is a common finding during sleep studies and is related to the movement of venous blood from the lower torso and legs as the body is upright during the first hour of bed rest to more evenly redistribute the blood across the length of the recumbent body. Segment C is at Figure 8C The time extension in Fig. 8E Further time extension in Fig. 8A Also noted in the ECi graph, segment E is the raw data trend that typically occurs with turning over; it includes a sudden, tandem baseline shift in both the red and infrared data values, which is due to the normal transfer of venous blood from one side of the body to the other due to gravity.
[0128] Figure 8C Is from Fig. 8A The time-extended segment C of the ECi recording in FIG. 1 also shows the boxed Fig. 8A and Figure 8B804 and has time values on the x-axis at 10 minute time intervals 804. The large deviations seen in the previous graphs are not "noise" in the sense that they vary smoothly over a period of several minutes. To relate this to more familiar measurements, parallel recordings made with a pulse oximeter sensor while a subject was breathing nitrogen have correlated ECi values less than -300 with a drop to SpO2 below 70%.
[0129] Fig.8D is corresponding to Figure 8C The original data plot of the ECi trend in FIG. 1 also shows the nested time segment D, which is also Fig. 8A and Figure 8B 804, where both the red signal intensity trace 612 and the infrared signal intensity trace 610 are shown. The different response patterns of the red signal intensity trace 612 and the infrared signal intensity trace 610 are shown to indicate that these deviations are not due to the series mode caused by sensor movement or breathing, but due to distortions in the cellular oxygen supply state of the skin. Two prominent single-breath obstructions 810 are seen, but most of the record is during periodic breathing (i.e., snoring) with a variably restricted airway. The sudden series change in the baseline intensity 812 of the red signal intensity trace 612 and the infrared signal intensity trace 610 occurs with the person turning over; in this case, sleeping on the side that places the sensor above the heart, thus presenting less absorption of both red and infrared light by venous blood. There is also a period of about 8 minutes after turning over 814, when the blood volume in the skin below the sensor continues to decrease and then stabilizes.
[0130] Fig. 8E Is from FIG. 8A to FIG. 8D 612 and 610. This signal pattern can be identified from a parallel PSG study in which the PSG microphone detected snoring over a long period of time with a nearly identical trend pattern, with little or no deviation from the "normal range" of SpO2 values. This 7+ minute segment is a recording of periodic breathing and severe snoring, but without airway obstruction. Similar ECi trends occurred during the parallel PSG recordings, including normal nasal air flow and normal patterns and ranges of movement of the chest and abdominal sensor bands (with snoring). The PSG data show that despite the subject's partially obstructed airway, the breathing effort was sufficient to move a normal amount of air with each breath. However, this ECi raw data pattern of periodic breathing and the corresponding cycles of skin hypoxic Eci response during snoring are clear indications of a physiological response to stress, which is likely to be a measurable "missing link" connecting snoring during sleep and the development of hypertension.
[0131] The period begins with normal breathing 816, then enters an initial 2 minute period of snoring 818. Increasing skin hypoxia and presumably a drop in SpO2 triggers arousal and several deeper breathing efforts 820, which are sufficient to almost completely return to a normal state. However, snoring resumes 818, and within a 1 minute period, the skin returns to a state of deep hypoxia. This pattern repeats at least three more times in this segment, but as Fig.8D As shown in , this snoring episode lasts for more than 15 minutes and ends only when the person wakes up, turns over, and resumes normal breathing after a total of about 35 minutes.
[0132] The disclosed ECM sensor 100 can be used for home-based diagnostic testing for SDB during sleep in children, adolescents, and adults. The home-based testing application can perform real-time or near real-time monitoring from a remote location and will be guided by a licensed and qualified physician who will analyze the data generated, diagnose the patient's condition based on the patient's medical history and recorded data, and prescribe the required treatment.
[0133] Figure 9A to Fig.9E Five sleep recording segments are presented that illustrate when and in which direction ECi data can be used to trigger APAP changes in airway pressure. The graphs include an infrared intensity trace 610 and a red signal intensity trace 612. Figure 7C The sleep breathing pathology also depicted in FIG. 1 begins with a transition from variable restricted breathing 710 of light snoring with periodic slight skin hypoxia 902 to a complete airway obstruction event 904. If the breathing pattern had been detected at the first arrow 902 during snoring, and the airway pressure had increased immediately, the complete airway obstruction event 904 might not have been too severe, or might not have occurred at all. If there was no abnormal breathing before the complete airway obstruction event 712, the ECi detection of the complete airway obstruction event 904 would have also triggered an immediate increase in airway pressure to reduce the problem.
[0134] Another example 910 is shown in FIG. 9B , which is taken from Fig. 8E At the beginning of the recording in , potential trigger points for APAP machine air pressure control begin with a period of large changes in breathing depth 912, followed by airway restriction 916 severe enough to produce a large non-tandem red intensity signal 612 value drop in segment 914 that may be associated with severe snoring. If the changes in breathing depth 912 or effort did not trigger an increase in airway pressure, the large non-tandem red intensity signal value drop at 914 should trigger an increase in airway pressure. Also of note are the changes in breathing pattern 918 that naturally interrupt the skin tissue hypoxia events 916. This may represent minor arousals and interruptions in sleep, but as Fig. 8EAs shown in the more detailed record illustrated in , the onset of SDB cannot be avoided.
[0135] Another example 920 is in FIG. 9C and relates to a toss during sleep occurring at 922, characterized by one or more large series changes 924 in the red and infrared raw data signals. This pattern entails triggering an immediate drop in airway pressure. There may or may not be dyspnea causing the toss, but one of the more annoying aspects of airway pressure therapy is waking up to find the APAP pressure is high, and remains high, while fully awake and breathing normally, when tossing. The ECM detects tossing by a series shift in the red and infrared signals 926, as venous blood moves to the opposite side of the body. The APAP air pressure and flow sensors cannot detect when a person has awoken from sleep enough to change position. It is unlikely that a person will continue any SDB event that occurred just prior to tossing.
[0136] Another example 930 in FIG. 9D shows how the ECM can detect central sleep apnea (CSA) and make appropriate pressure changes in response. Figure 7C , between about 4 and 6 minutes, shows a restricted airway associated with an obstructive apnea 716 preceding a central apnea 718. APAP therapy requires recognition and aggressive treatment of obstructive events with higher pressures. However, if higher pressures induce apneas (such as at arrow 932), it can reduce pressure, or possibly provide tactile stimulation to help abort the episode of central apnea.
[0137] Fig.9E is Figure 7C9A , and no evidence of effective breathing effort 714 is shown for more than one minute. While most adults with this SDB pattern may continue to sleep (albeit with less than desired sleep quality), infants with similar patterns may be at increased risk of SIDS; and may not survive! The disclosed ECM sensor is capable of detecting and providing identifiable data features of these potentially life-threatening events as they occur, and triggering an alarm (such as at arrow 902 in FIG. 9A ), or triggering some other stimulus, such as turning on a buzzer vibrator motor (tactile stimulus) included in the sensor housing in the case of a SIDS risk infant, which may be reliable enough to wake the person up to resume effective breathing. Some children and adults with SDB also have periods of central apnea while receiving airway therapy if the airway pressure from the airway therapy device increases in response to an OSA event, but becomes too high. This phenomenon is considered by sleep medicine experts to be a reflex inhibition of normal respiratory drive by stimulation caused by airway pressure of stretch receptors within the human lungs. An effective response has been found to be to immediately reduce airway pressure. However, consistently and effectively detecting this condition with current airway therapy devices is a persistent problem. Fortunately, most people with this response eventually "get used to" higher than required pressures and can tolerate lapses in machine-controlled response. ECM provides a new way to detect periods of CSA interspersed with OSA; therefore, potentially providing a more accurate APAP machine response to these events.
[0138] FIG. 10A to FIG. 10D Graphs show the calculation and characteristics of sensor signal trends from sensor monitoring devices. Fig. 10A Measure the index value (Y-axis) over time (X-axis); Fig. 10B Measures intensity (Y-axis) over time (X-axis); Fig. 10C Measures the percentage of saturation (Y-axis) over time (X-axis). Fig. 10D Is a schematic representation of the relative absorbance of light at two central wavelengths (Y-axis) and the energy conversion index value (X-axis) calculated from the resulting detection signal intensity values as a function of cellular oxygen supply. The X-axis runs from very low oxygen supply on the left through normal oxygen supply to excess oxygen supply on the right.
[0139] like Fig. 10AAs shown in , the present disclosure uses detected light intensity values (I) at two wavelengths: 685 nm (red) 1002 and 850 nm (infrared) 1004. By subtracting the detected 850 nm intensity value 1004 from the detected 685 nm intensity value 1002, output data calculated as an energy conversion index (ECi) 1006 is obtained. When these data are obtained while the subject is breathing nitrogen (N2) gas 1008, an ECi trend 1010 is generated. For example, the data can be obtained at a rate of once per second. Go to Fig. 10B , the raw data 1012 from which the ECi trend 1010 is calculated has been shown to have consistent response characteristics relative to the physiological and biochemical stresses imposed on the monitored skin tissue. In general, the 850 nm trend 1014 changes cyclically with the subject's respiratory effort, but is not affected when the oxygen supply to the skin tissue is subnormal to normal. The 685 nm trend 1016 is slightly less affected by respiration, but this wavelength is absorbed more when the oxygen supply to the monitored skin tissue is reduced. Fig. 10C The pulse oximetry (SpO2) data 1018 recorded simultaneously in FIG. 1010 shows the changes in blood oxygen caused by breathing nitrogen. Note the delayed SpO2 response at the beginning and end of this event.
[0140] The relative absorbance response for the two wavelengths is Fig. 10D As shown graphically above. As the oxygen supply to the skin tissue decreases relative to normal areas, the 685 nm light 1020 is increasingly absorbed, but the absorption rate of the 850 nm light 1022 remains unchanged. Increasing the oxygen supply above normal levels causes a certain continued decrease in the absorption rate of the 685 nm light 1020, while the absorption rate of the 850 nm light 1022 increases dramatically. Thus, approaching the threshold of entering excess oxygen supply 1024 can be recognized as the time when the absorption of the 850 nm light 1022 begins to increase while the absorption of the light 1020 at 685 nm continues to decrease and then remains stable.
[0141] Figure 11A to Fig. 11B Energy conversion index data from an ischemia / reperfusion spectral absorption test using broadband light illumination of the forearm skin and a spectrometer for signal detection is illustrated. As shown in FIG. 12 , spectrometer detected light intensity values at 685 nm and 850 nm are selected from the recorded spectrometer data file and used as raw data to calculate an energy conversion index value trend 1110. In FIG. 11A , the energy conversion index value trend 1110 is measured on the Y axis and time is measured on the X axis. Fig. 11BIn the test, the detection light intensity at 850 nm 1104 and 685 nm 1106 is measured on the Y axis, and time is measured on the X axis. This is a brief, harmless and easily reproducible demonstration that simulates blood volume and tissue chemistry dynamic changes, which may also occur during the occlusion of the blood supply to vital organ tissues, and then during reperfusion, such as ischemic heart attack, ischemic stroke or the reperfusion of transplanted organs. The test uses a pneumatic cuff on the upper arm of the subject to stop blood from flowing into and out of the forearm within three minutes, and then suddenly releases the cuff pressure to allow blood flow to recover. The test uses a spectrometer (Ocean Optics, Flame-S) for signal detection of non-absorbed light after broadband light has passed through 8 mm of the subject's forearm skin via optical fiber (Ocean Optics QTH lamp). Detect and record the spectral light intensity data from 600 nm to 1000 nm once per second. The pre-test reference spectrum is subtracted element by element from each sample spectrum and the difference spectral data values are recorded. If no changes in absorption occur in the forearm skin during the recording period, the resulting spectral intensity change data will always be close to zero.
[0142] like Fig. 11B 11A , the data in FIG. 11A is calculated by subtracting the recorded 850 nm infrared intensity values 1104 from the time corresponding 685 nm red intensity values 1106, thereby generating an energy conversion index value trend 1110. It has been found that infrared wavelengths are most sensitive to the volume of blood (mostly venous) within the optical path. When the cuff is rapidly inflated 1112, blood flow into and out of the forearm stops completely, causing the 850 nm data trend of the infrared intensity values 1104 to change very little. On the other hand, the 685 nm red value trend for the red intensity values 1106 shows a continued increase in absorption (a decrease in detected signal intensity) during the entire cuff inflation period 1114. Time point "A" 1116 is just before the cuff pressure is released, and "B" 1118 is shortly after the cuff pressure is released 1120, when the signal has stabilized again.
[0143] When the cuff pressure is released 1120, arterial blood flow into the forearm is restored before venous blood is allowed to begin leaving the forearm, causing a small amount of additional blood to accumulate briefly in the forearm and causing a slight drop in the 850 nm trend 1122. On the other hand, the intensity value 1124 at 685 nm rises very quickly to a much higher value 1126 than before the cuff was inflated, indicating that the skin absorbs less at 685 nm, as also occurs when a person breathes 100% oxygen (i.e., cellular hyperoxia). Simultaneous recording of pulse oximetry during this test typically shows only slight changes in SpO2 from the beginning to the end of the test, or even no change. The combination of much less absorption at 685 nm than before the test, and slightly more absorption at 850 nm upon reperfusion, while the arterial oxygen saturation of pulse oximetry does not change, presents evidence that oxygen saturation plays only a very small role. Therefore, the large changes in the recording of spectral optical density during this test are likely to be primarily due to changes in cellular chemistry. The main meaning of this simple demonstration is that the reperfusion injury of adult vital organs and the eye, brain and intestinal damage that occur in premature newborns may be the result of previously unknown or underappreciated cell adaptation to low oxygen supply. From experiments such as this test, the cell energy conversion mechanism such as mitochondrial transport in the cell seems to be more time efficient in adapting to the sudden reduction of oxygen supply than in adapting to the sudden increase of oxygen supply. Current research on ischemia / reperfusion injury (IRI) clearly defines the first few seconds of reperfusion (rather than during the previous ischemic or hypoxic period) as the time when major problems such as white blood cell adhesion in capillaries and venules begin to appear, which lead to blood flow obstruction, which eventually causes cell death in the surrounding tissues.
[0144] Figure 12A to Fig. 12B Exemplary skin spectral absorbance changes just before and after blood return are illustrated as FIGS. 11A to 11B. Fig. 11B An alternative depiction of the test data depicted in FIG. 12A to FIG. Fig. 12B The absorbance change (Y-axis) or net change in spectral absorbance over the wavelength range from 600 nm to 1000 nm (X-axis) is shown for two data samples (Sample A and Sample B). These spectral records are used to help select the most active areas of the spectrum relative to changing skin cell oxygen supply. In extreme cases of complete cessation of blood flow or ischemia, the cellular chemical impact is theoretically greatest, leading one to believe that this test may be the best way to limit the sensor wavelength. The spectrum 1200 of Sample A, recorded just before the cuff was released, shows a maximum absorbance change 1202 at approximately 685 nm. On the other hand, the infrared wavelength is most affected immediately after reperfusion in Sample B, with the maximum absorbance change 1212 shift occurring at approximately 850 nm 1204.
[0145] Figure 13A to Fig.13D Results of an exemplary exercise recording 1300 illustrating trends of the Energy Conversion Index (ECi) 1302, raw data 1304, PPG heart rate 1306, and SpO2 1308. FIG13A shows index values (Y-axis) over time (X-axis); Fig. 13B The intensity (Y-axis) is plotted over time (X-axis); Fig. 13C shows the number of heart beats per minute (Y-axis) versus time (X-axis); and Fig.13D The SpO2 percentage (Y-axis) is shown as a function of time (X-axis). The data was acquired simultaneously from adult athletes during a stationary bicycle exercise session. Fig. 13B The raw data 1304 shown in , shows a decrease (higher signal intensity) in the sensor's absorption of 850 nm light 1310 relative to the level of exertion. Normal hypoxic stress induced by exercise is known to drive reflex vasoconstriction of the blood supply to the skin to preserve cardiac output and systemic oxygen consumption, thereby preferentially maintaining vital organs (brain and heart). When less blood is delivered to the skin, there is less absorption of the sensor's light; this is more obvious using the infrared wavelength 1310. For each of the three intervals of increasing effort, there is also a progressive change in the absorption of red light relative to infrared light that appears to be associated with an adaptive response to hypoxic stress that appears to be uniquely and robustly detected by the present disclosure. Despite similar levels of exertion, gradually less obvious differential responses 1312, 1314, and 1316 are seen in the raw data 1304, as shown in FIG. Fig. 13C , resulting in an overall ECi trend 1318 toward the pattern seen with excess cellular oxygen delivery or skin hyperoxia 1320. Notably, during and after the exercise session in this healthy athlete, Fig.13D The SpO2 data in is virtually unchanged. Apparently, during this exercise session, a combination of physiological stabilization reflexes activated resulted in a completely continuous blood oxygen supply to the athlete's brain, heart, and muscles.
[0146] Figure 14A to Fig. 14B An exemplary recording during normal sleep breathing is illustrated. Figure 14A is a 6:50 hour segment of an Energy Conversion Index sleep recording 1402 that depicts the level of oxygen supply to the skin under the sensor relative to a person's normal, adapted state while awake. Fig. 14B1404 is the raw data used to calculate the Energy Conversion Index sleep log 1402. It is known that this person does not snore and sleeps well throughout the night. The first four hours of sleep 1406 were not disturbed by dyspnea. Only brief bursts of minor activity are seen in the ECi and raw data trends 1408, and since most of these changes are in tandem, they do not show a significant reduction in oxygen supply to the subject's skin.
[0147] Figure 15A to Fig. 15B An exemplary recording during severe sleep disordered breathing is illustrated. FIG. 15A is a 7-hour energy conversion index recording 1502 showing several abnormal responses that may occur during sleep. The initial hour 1504 of the raw data 1506 typically follows a tandem downward trend as evidence of a shift in systemic blood volume to be distributed over the entire supine length of the body. During the remainder of the night, the raw data baseline typically shifts 1508 upward or downward in tandem depending on the side-to-side position of the subject's body. Fig. 15B As shown in the raw data 1506 record corresponding to FIG. 15A , when the sensor is below the subject's heart on the arm, the raw data 1506 baseline is lower due to the presence of more venous blood in the skin of the monitored arm. The opposite occurs when the subject rolls over and sleeps with the sensor above the heart. The reduction in skin tissue oxygen supply is detected by the difference 1510 that the red trend is less than the infrared trend, which results in a negative energy conversion index trend 1512.
[0148] It is apparent that the breathing difficulties during sleep were not consistent throughout the night. Of note is the boxed episode 1514 during which the subject's oxygen supply was severely affected by breathing problems. This data segment is shown in Figures 15C to Fig.15D Medium expansion.
[0149] Figure 15C to Fig.15D Figure 15A to 15B shows the time course of restricted and periodic breathing. Fig. 15B1514 segment of the framed episode. The oscillating ECi pattern typically seen with periodic breathing 1516 is the most notable feature of this segment. Periodic breathing during sleep is characterized by moderate airway restriction, which typically produces snoring. Research literature describes sleep deprivation as the cause of reduced sensitivity to low oxygen intake during periodic breathing. This reduced sensitivity causes a delayed response to hypoxic stress, resulting in repeated cycles of deeper "catch-up" breathing typically at intervals of 25-35 seconds due to increased loop gain. The raw data infrared trend baseline 1518 in this recording remains relatively constant, while the red trend 1520 forms a periodic drop, indicating that the oxygen supply to the skin is periodically below normal levels. The 10 minute episodes of widely varying and more extreme airway restriction 1522 are clearly interrupted by obstruction events 1524, which awaken the person to a lighter sleep stage and less severe airway restriction.
[0150] Figure 16A to Fig. 16B An exemplary record during severe sleep disordered breathing with both obstructive and central apnea is illustrated. The record covers an 8-minute segment during a series of severe airway obstructive episodes that extend during sleep. The first two minutes of the record show a huge series change in the raw data typical of activities with severe airway distress, which causes a sharp decline in the energy conversion index trend. From the 2nd minute, there is a period 1602 with reduced respiratory drive or central apnea, accompanied by significant skin hypoxia, which drops to about -275 on the energy conversion index scale. This apnea period is followed by regular, obviously unobstructed breathing, which causes a gradual energy conversion index recovery trend towards normal skin oxygen supply, but this is interrupted by a large obstructive event 1604. After this airway obstruction event, there is a 3-minute central apnea period 1606, accompanied by a large respiratory effort for most of the obstructed airways, thereby causing moderate skin hypoxia. The record segment ends with irregular breathing 1608 for less restricted airways, but oxygen intake is almost not improved.
[0151] Fig.17AAn exemplary dual probe sensor 1700 is illustrated, which consists of a central hub 1702 connected to a first skin contact probe assembly 1704 and a second skin contact probe assembly 1706. The first skin contact probe assembly 1704 and the second skin contact probe assembly 1706 are connected by optical fibers. Two LEDs 1708 of 685 nm and 850 nm alternately project light via a first optical fiber 1710 to a reflector and an orifice 1712, which project light into the tissue on which the first skin contact probe assembly 1704 is placed. The light is diffused by the tissue 1714, and a sample of the light that is not absorbed is transmitted to a photodetector 1720 through a second optical fiber 1718. Light is also simultaneously transmitted to and from the second skin contact probe assembly 1706 and is detected by the second detector in a similar manner. It is desirable to illuminate both the first skin contact probe assembly 1704 and the second skin contact probe assembly 1706 simultaneously with LED light of the same central wavelength to reduce the ambiguity of the difference results. This configuration can be used non-invasively for two skin application sites, such as the pre-ductal and post-ductal sites located on the right upper chest and left lower abdomen of a premature newborn, respectively. By this means, the pre-ductal probe data will indicate the highest oxygen supply state, and the post-ductal probe indicates the lowest oxygen supply state. This information can be used to guide the initial and sustained oxygen fraction in the respiratory gas, and indicate when the catheter is closed; or if the catheter is not closed in a timely manner and becomes a problem. This configuration can also be applied as a "normal standard" to a first skin contact probe assembly 1704 placed on the skin of an organ recipient, and to a second skin contact probe assembly 1706 placed on a transplanted organ during reperfusion and surgical implantation of the organ to monitor the reperfusion and resupply of oxygen to the transplanted organ. Fig. 17B An alternative embodiment in would have the same configuration as a first skin contact probe assembly 1704 for placement on a patient's skin as a "normal standard," with optical fibers leading to 1722 and from 1724 the monitored tissue 1726 via a needle inserted into the tissue to interface with the tissue. This format may be more useful when access to the monitored tissue is limited, or when surgical access for placement of an organ surface contact probe needs to be avoided.
[0152] Once the ECM device engages the patient's skin, the aforementioned initialization and operation of the sensor is performed. Detection of unabsorbed light from the emitted light after the light has passed through the skin is performed using a light detector. Once the unabsorbed light is detected, the differential photon absorption effect is calculated to determine the level of skin hypoxia. A light detector such as a silicon PIN photodiode detects both 685 nm and 850 nm light in a known spectral response manner. The method may also include providing feedback control of the operation of the ECM device. Feedback control includes, but is not limited to, increasing or decreasing the intensity of the emitted light. The method may also include generating an energy conversion index output by subtracting a first detected intensity from the 850 nm light from a second detected intensity from the 685 nm light.
[0153] In another method, the ECM device is used in combination with an airway treatment device. An airway treatment device such as a CPAP device or an APAP device has a blower, a patient interface, an air delivery conduit for delivering air from the blower to the patient interface, a sensor for determining the pressure in the patient interface, and a control mechanism, which enables air to be delivered to the patient interface at a desired pressure, and detects the transition between inhalation and exhalation of the patient's breathing cycle, so as to synchronize the blower output with the patient's efforts. The method includes transmitting data from the ECM device to the airway treatment device. The data from the ECM device can be transmitted directly to the airway treatment device, indirectly to the airway treatment device, wirelessly to the airway treatment device, or wired to the airway treatment device. The data from the ECM device can be used to change the operation of the airway treatment device. In other methods, the data from the ECM device can be analyzed at a remote central location, and then instructions for the operation of the airway treatment device can be sent to the airway treatment device to adjust the performance of the airway treatment device during the operation of the airway treatment device or during the next use of the patient.
[0154] In another method, an ECM device is used in conjunction with a PSG test instrument. The PSG test instrument includes the use of sensors and devices to monitor brain waves, eye movements, heart rate, breathing patterns, blood oxygen levels, body position, chest and abdominal movements, limb movements, snoring, and other sounds. The method includes transmitting data from the ECM device to a central computing device that receives information related to the polysomnography test. The data from the ECM device can be transmitted directly, indirectly, wirelessly, or by wire. The data from the ECM device can be used to facilitate the diagnosis of SDB. The same method using the ECM device can also be applied to the use of home sleep apnea testing alone or in combination with other devices.
[0155] Systems and methods according to aspects of the disclosed subject matter may utilize a variety of computers and computing systems, communication devices, networks, and / or digital / logic devices to operate in combination with the disclosed sensors. Each in turn may be configured to utilize a suitable computing device that may be manufactured with, loaded with, and / or retrieved from a storage device and then execute instructions that cause the computing device to perform methods according to aspects of the disclosed subject matter.
[0156] Computing devices may include, but are not limited to, mobile user devices such as mobile phones, smart phones and cellular phones, personal digital assistants (PDAs) such as iPhone®, tablet computers, laptop computers, etc. In at least some configurations, a user may execute a browser application over a network such as the Internet to view and interact with digital content such as screen display content. The display includes, for example, an interface that allows visual presentation of data from the computing device. Access may be through or in part through other forms of computing and / or communication networks. A user may access a web browser, for example, to provide access to applications and data located on a website or web page of a website and other content.
[0157] Suitable computing devices may include processors to perform logic and other computing operations, such as independent computer processing units (CPUs), or hard-wired logic such as in microcontrollers, or a combination of the two, and may execute instructions according to their operating systems and instructions to perform the steps of the method or elements of the process. The user's computing device may be part of a network of computing devices, and the methods of the disclosed subject matter may be performed by different computing devices associated with the network, which may be in different physical locations, collaborate or otherwise interact to perform the disclosed methods. For example, a user's portable computing device may run an application alone or in combination with a remote computing device such as a server on the Internet. For the purposes of this application, the term "computing device" includes any and all of the logic circuits, communication devices, and digital processing capabilities discussed above or a combination of these.
[0158] For illustrative purposes, certain embodiments of the disclosed subject matter may be described as steps of a method that can be executed on a computing device that executes software, and are illustrated as a block diagram of a process flow by way of example only. This may also be considered a software flow chart. Such block diagrams and similar operational diagrams of the method or operation of the computing device executed and any combination of the blocks in the block diagram may be provided as example diagrams to the software program code / instructions of the computing device, or at least a brief statement of the functions and operations performed by the computing device when executing the instructions. Some possible alternative implementations may involve functions, functions, and operations marked in the boxes of the block diagram, which do not occur in the order marked in the block diagram, including occurring simultaneously or nearly simultaneously, or occurring in another order or not occurring at all. Aspects of the disclosed subject matter may be implemented in parallel or serially in hardware, firmware, software, or any combination of these, which are at least partially co-located or remotely located relative to each other, such as in an array or network of computing devices, through an interconnected network including the Internet, etc.
[0159] Instructions may be stored on a suitable "machine-readable medium" within a computing device, or communicate with the computing device, or otherwise be accessible by the computing device. As used in this application, a machine-readable medium is a tangible storage device, and instructions are stored in a non-temporary manner. At the same time, during operation, instructions may sometimes be temporary, such as being transmitted from a remote storage device to a computing device via a communication link. However, when the machine-readable medium is tangible and non-temporary, the instructions will be stored in a memory storage device such as a random access memory (RAM), a read-only memory (ROM), a magnetic disk or optical disk storage device, etc., for at least a period of time, and the array and / or combination of the memory storage device may form, for example, a local cache memory residing on a processor integrated circuit, a local main memory such as a local electronic or hard drive contained in a shell for a processor of a computing device, a remote storage location of a remote server connected to a local server or accessed via a network, etc. When stored in this way, the software will constitute a "machine-readable medium" that is both tangible and stores instructions in a non-temporary form. Thus, at a minimum, a machine-readable medium storing instructions for execution on an associated computing device would be “tangible” and “non-transitory” when the instructions are executed by a processor of the computing device and when the instructions are stored for subsequent access by the computing device.
[0160] In addition, the communication system of the present disclosure includes: a sensor as disclosed; a server computer system; a measurement module on the server computer system, which is used to allow the measurement values from the detection device to be transmitted over the network. The communication capability also includes the ability to convey and display relevant performance information to the user, and supports both ANT+ and Bluetooth Smart wireless communications. A storage module on the server computer system can also be provided for storing the measurement values in the detection device server database. In some system configurations, the detection device can be connected to the server computer system through at least one of a mobile phone network and an Internet network, and a browser on the measurement recipient electronic device is used to retrieve an interface on the server computer system. In some other configurations, the system further includes: an interface on the server computer system, which can be retrieved by an application on a mobile device. In addition, the server computer system can be configured so that it can be connected through a cellular telephone network to receive a response from the measurement recipient mobile device.
[0161] Usage Examples
[0162] Examples of use relate to the use of the disclosed ECM sensor alone or as part of a system with one or more auxiliary devices. The auxiliary device may be selected from a second sensor, a sleep disordered breathing (SDB) treatment device, a remote computing device, and a polysomnography (PSG) system.
[0163] Additionally, the operation of the ECM sensor or system may be controlled directly by a user (i.e., by docking with the sensor), or via a software application on a mobile computing device, such as a smartphone or tablet, that is configured to wirelessly control the ECM sensor. In other configurations, the ECM sensor or system may be operated via a remote computing device that wirelessly communicates with the ECM sensor (e.g., from a clinic or healthcare practitioner facility).
[0164] Sleep-disordered breathing
[0165] In one example, the disclosed sensor can be used to aid in the diagnosis of sleep disordered breathing (SDB). The clinical utility of the disclosed ECM sensor for adult diagnostic testing of SDB has been demonstrated in a proof-of-concept (POC) PSG sleep study conducted at the UCSF Sleep Disorders Center at Mt. Zion Hospital in San Francisco. The disclosed ECM sensor was also found to be suitable for remote SDB testing at home. The UCSF POC sleep study demonstrated that ECM detection of cellular hypoxia in the skin during prolonged snoring is an important new finding that has the potential to be used by healthcare professionals to better understand and define the physiological mechanism(s) of increased statistical risk for SDB comorbidities such as hypertension, atrial fibrillation, heart attack, stroke, and early-onset dementia. PSG pulse oximeter data during the POC study did not detect a "scorable" drop in SpO2 (e.g., a drop of 3% or more) during most snoring episodes, and only showed a drop in arterial oxygen during more severe and prolonged episodes of OSA and CSA. PSG instruments currently only include pulse oximetry as a means of monitoring oxygen intake.
[0166] As those skilled in the art will appreciate, PSG measurements of respiratory effort use stretch-sensitive belts around the chest and abdomen and an air flow sensor placed near the nose to provide a rough estimate of the effort required for each breath, and how that effort correlates to the movement of air into and out of the lungs. A more effective mechanism for measuring respiratory effort is to track the pressure within the chest cavity using an intraesophageal balloon manometer. However, this method is quite uncomfortable and is rarely used clinically. The additional ability of the disclosed ECM sensor to non-invasively detect the timing and relative effort of each breath improves and simplifies the detection of OSA versus CSA compared to current PSG systems. The UCSF POC study demonstrated that the ECM raw data also clearly distinguishes OSA from CSA through the detection of respiratory rate and respiratory effort via an infrared channel. It is known that venous blood flows into and out of the central chest veins with each breath, and correspondingly into and out of the peripheral veins. This respiratory circulating venous blood flow is Pulsus paradoxus The ECM's infrared channel data optoelectronically detects subtle changes in venous blood volume in the skin at the sensor site on the upper arm as cyclical changes in signal intensity at infrared wavelengths. This provides a non-invasive "phlebotomy" of intrathoracic pressure that may be comparable in quality and sensitivity to invasive intraesophageal balloon manometry.
[0167] The data recorded at home each night using the ECM sensor can be transmitted, for example, via cell phone data transfer, to a "back-end" service center where a qualified and licensed sleep medicine specialist will review the data and, if their evaluation indicates it is necessary, a prescription for an airway therapy device will be returned to the patient's physician and respiratory therapist. The sleep medicine specialist who reads the home diagnostic test data can recommend that the patient undergo a formal PSG sleep study based on the expert evaluation for further evaluation of complex cases, such as those with underlying neurological conditions, seizures that occurred during the sleep recording, and other disabilities that can adversely affect the quality of the diagnosis and may require more complex treatment of SDB.
[0168] In another related application, the disclosed sensor can be used to record the body position of adults with SDB during sleep at home. Adults typically have more severe OSA and snore when sleeping in the supine position. In fact, all sleep recordings made using ECM show an initial period of about one hour when venous blood is redistributed from being primarily distributed in the lower torso and legs when upright to being more evenly distributed over the entire length of the supine body during sleep (i.e., rostral shift). In addition, when a sleeper with the ECM applied to the upper arm rolls over from side to side, there is a further shift in the venous blood volume in the skin beneath the sensor, resulting in large, sudden series shifts in both the red and infrared signals, depending on which side the person is lying on. Therefore, continuous detection of body position and posture during sleep is needed, and in the present disclosure, this can be further recorded by system integration with a microelectromechanical system (MEMS) accelerometer.
[0169] In a related application, the disclosed sensors may be used to remotely guide titration of SDB therapy (such as with an APAP machine) at home to optimally titrate a patient's therapy while they sleep at home. Airway therapy devices currently used in sleep laboratories for titration of airway therapy use more advanced sensors and controllers than are typically found in airway therapy devices prescribed for home use. The sleep laboratory technician performing therapy titration also has real-time access to a full array of PSG instruments as well as infrared video surveillance of the person being tested. This higher quality and complete information assists the sleep test technician in managing therapy during the titration process. Prescriptions for home airway therapy devices by sleep medicine specialists are largely derived from observational and recorded data from the procedure. However, due to differences between clinical and home therapy devices, sleep laboratory therapy titrations and derived prescriptions for home machine settings may not produce optimal results for a home machine. Remote titration utilizing the disclosed sensors is more likely to be successful in both initial and subsequent optimization of home therapy.
[0170] In another related application, the disclosed sensor can be used to help control SDB treatment equipment in the patient's home. Compared with a complete PSG system including a trained sleep test technician and a clinical quality APAP machine, existing home airway treatment equipment is significantly limited in its sensitivity and specificity in detecting SDB events. Typically, home APAP machines cannot clearly distinguish between OSA, snoring, and CSA events because the machine is limited to sensing airway pressure and air flow via a hose from the machine to the patient's nasal mask or face mask. OSA and snoring are typically better resolved with an increase in airway pressure. On the other hand, long-term apnea (such as CSA) is usually in response to a drop in airway pressure. Airway treatment equipment that cannot accurately distinguish and implement opposite treatment options is unlikely to provide optimal treatment. In addition, home airway treatment equipment does not include monitoring the patient's arterial oxygen status as done with a PSG system pulse oximeter. Adding the enhanced physiological insight provided by ECM to the sensor capabilities of home airway treatment equipment potentially provides a much richer information library or data set based on which treatment is adjusted. Furthermore, the disclosed therapeutic systems can potentially detect and automatically respond to even subtle changes in a patient's therapeutic needs over time.
[0171] In another related application, the disclosed sensor system can obtain nightly recordings from the disclosed sensors during sleep, which can be electronically transmitted to a central data repository for research and as a mechanism for continuous monitoring of individual patients. Automated algorithms can be configured to scan data as it arrives and compare it to previous records for the same patient to detect whether significant changes have occurred; thus, generating a daily "case review" list for targeted evaluation by sleep medicine specialists. This growing database of SDB information can also be used to link with research in comorbid areas including neurology, pulmonology, and cardiology. Qualified sleep medicine physicians have identified the widely published but poorly understood statistical link between snoring and risk of hypertension as a high priority for future research using ECM sensors to identify and more clearly define the causal link. Preliminary evidence shows that cellular hypoxia in the skin occurs at the beginning of the snoring period of sleep and persists throughout the duration of snoring. The UCSF POC study demonstrated that the ECM sensor provides key missing information that is not and cannot be produced by pulse oximetry in current technology PSG sleep studies. The addition of ECM recording to PSG testing is expected to enhance the sensitivity and specificity of the “gold standard” diagnostic method.
[0172] In another related application, the disclosed sensors may be used for continuous or intermittent SDB monitoring of a person receiving treatment at home. As stated above, one of the most serious current deficiencies in clinical SDB treatment is the lack of objective monitoring after diagnosis and initial titration of treatment devices in a well-equipped sleep laboratory. The human body inevitably ages over time and becomes less physiologically stable - ultimately resulting in death. The use of ECM as an integral component of continuous airway therapy control combined with cell phone text or Internet data transmission to back-end sleep medicine professional service organizations allows for continuous, objective, and relevant monitoring and professional guidance over time. Early detection of new health issues that worsen or affect SDB could be a significant and potentially life-saving benefit of such an integrated care system.
[0173] Home Monitoring and Surveillance After Hospital Discharge
[0174] In another example, the disclosed sensor can be used to provide continuous monitoring of adults with chronic diseases after discharge from the hospital. Continuous home monitoring of chronic heart failure and chronic lung disease in the elderly requires an integrated approach. Abnormal breathing and other common forms of physiological stress cannot be monitored at home with the sensitivity and responsiveness required to optimally monitor these key variables. As patients recover in the hospital and are discharged home, armband ECM sensors can provide useful monitoring of delayed onset complications.
[0175] Monitoring of cellular oxygen supply during and after anesthesia
[0176] In another example, the disclosed sensor may be used to provide cellular oxygen supply monitoring to patients undergoing surgical anesthesia and during their post-anesthesia recovery. The demonstrated diagnostic advantages of the disclosed sensor in detecting abnormal ventilation of the lungs and detecting insufficient and excessive oxygen intake compared to pulse oximetry provide significant benefits to patients and improve clinical guidance during and after surgery. The additional sensitivity of the disclosed sensor to reduced skin perfusion and reduced cellular oxygen delivery to the skin provides a highly relevant new monitor for reduced blood volume and reduced blood oxygen carrying capacity due to blood loss and dilution of the blood with intravenous fluids, both of which are common risks during surgery, undetectable using pulse oximetry, and may not otherwise be identified until a life-threatening crisis occurs; potentially resulting in adverse consequences.
[0177] SIDS screening
[0178] In another example, the disclosed sensor can be used to screen newborns for risk of death from SIDS. Body position and posture during sleep have been identified as factors that exacerbate the condition in SDB and are clearly defined as part of the infant's risk of SIDS. When statistically compared to infants of equal risk sleeping on their stomachs, infants sleeping on their backs statistically have about half the risk of SIDS. It is known that infants typically have recurring periods of apnea or apnea during sleep, which is also referred to as periodic breathing. The disclosed sensor can be configured to detect when breathing timing and effort change in periodic phases as an indication of periodic breathing during sleep. The sensor system can be configured to detect a gradual increase in breathing effort with consecutive periodic breathing phases as an indication of a potentially fatal condition where a "runaway" loop gain may occur (such as may occur in infants at risk of SIDS). The sensor can be configured to implement an alarm response to detected "runaway" loop gain and prolonged apnea events to: (1) alert the caregiver for immediate intervention, and (2) simultaneously generate a mechanical vibrotactile stimulus on the infant's arm in an attempt to awaken the infant from sleep to abort the periodic breathing or potentially life-threatening prolonged central apnea.
[0179] Detection of reduced skin perfusion
[0180] Another useful application of the disclosed sensor is to detect a decrease in skin perfusion, such as at the onset of septic shock. The disclosed sensor will detect a decrease in skin perfusion by a decreasing detection intensity at 685 nm and a steady or increasing detection intensity at 850 nm light simultaneously, thereby producing a continuously decreasing ECi trend, typically initially detected by pulse oximetry with a stable SpO2. Clinical assessment of the onset of septic shock is currently performed using a capillary refill test procedure during routine vital sign checks during hospital care. However, the time interval between such checks and the need for a skilled clinician to perform the test often delays detection. The use of the disclosed sensor for continuous inpatient monitoring of patients considered at risk for sepsis provides a continuous, highly sensitive and responsive means of relevant monitoring to detect this common and potentially fatal complication of medical and surgical care. When applied during the period immediately following discharge, the disclosed sensor also provides clinical remote "early warning" monitoring; thereby potentially improving the quality of outcomes while enabling earlier discharge and reducing healthcare costs.
[0181] Reperfusion of ischemic tissue
[0182] In a dual interface example, the disclosed sensor can be used to guide reperfusion of ischemic tissue. The first sensor interface is placed on a normal reference tissue such as normally perfused skin, while the second interface is placed on an ischemic tissue (such as an affected portion of the myocardium of the heart during reperfusion therapy of an ischemic heart attack as an example). After an experimentally induced blood flow arrest period, detection of ECi trend overshoots when normal oxygen saturated blood is suddenly re-supplied to the monitored tissue is continuously seen. The intensity detected at 685 nm typically increases rapidly to a level much greater than the intensity from the reference unaffected sensor site, indicating that the tissue is currently adapting to a lower rate of cellular oxygen supply. The sensor can also be configured to: by detecting an increased intensity at 685 nm, while detecting a decreased intensity at 850 nm in response to an increase in oxygen content in the reperfused blood, indicating that the reperfused blood is supplying potentially damaging levels of oxygen to the monitored tissue, thereby achieving a therapeutic retreat of oxygen supply to a safer and more effective rate. The disclosed sensor can also provide feedback control data to automatically operate the venous / arterial blood mixing system of the reperfusion pump.
[0183] Organ transplantation
[0184] Another example of an application of the dual probe example of the disclosed sensor is to provide objective guidance on safely and effectively increasing oxygen supply in blood reperfusion of a transplanted organ, where the first sensor interface is placed on a reference "normal" tissue such as the patient's skin. In this application, the second sensor interface is placed in optical contact with the reperfused transplanted organ to indicate cellular tolerance of oxygen supplied by a variable mixture of venous and arterial perfusion blood, until only arterial blood is used without photonic evidence of cellular hyperoxia. The disclosed sensor can also provide feedback control data to automatically operate the venous / arterial blood mixing system.
[0185] Premature baby monitoring
[0186] In another application example of the dual interface example, the disclosed sensor can be applied to premature newborns to indicate that the monitored tissue (such as the pre-ductal skin of a premature newborn) is supplied with oxygen exceeding a safe and effective level by detecting an increase in intensity at 685 nm and a decrease in intensity at 850 nm in response to an increase in the oxygen fraction in the respiratory gas; thereby achieving a therapeutic retreat of the respiratory gas oxygen content to a safer and more effective rate. The disclosed sensor and associated new methods of use can be applied to help provide sufficient time for cells to adapt to higher oxygen availability, such as for newborns adapting to breathing air; thereby minimizing or preventing "oxidative stress" damage to the eyes, brain and other important organs. The disclosed sensor can also provide feedback control data to automatically operate the respiratory gas mixing system to adjust the oxygen level in a physiologically safe and effective manner.
[0187] athlete
[0188] In another example, the disclosed sensor can be used to provide continuous monitoring of athletes during and after exercise. It is well known to exercise physiologists and has been shown in published research literature that blood oxygen saturation, as measured by blood gases and SpO2, is not affected by strenuous physical activity in healthy adult athletes. Faster heart rate and deeper, faster breathing are well-known reflex-driven means of increased oxygen intake in response to increased oxygen consumption by working muscles. However, ECM recordings during strenuous physical activity have shown that there is also a natural microvascular response in the skin that reduces oxygen consumption in the skin, presumably to better meet the oxygen needs of working muscles and vital organs during exertion. The reduction in blood perfusion to the skin during strenuous physical activity always causes cellular hypoxia in the skin, which is detected by the ECM sensor; even without a drop in SpO2. Experimental recordings during multiple exercise sessions have demonstrated newly observed physiological response patterns that far exceed heart rate, heart rate variability analysis, and pulse oximetry in assessing the relationship between workload and a person's physiological reserve and response characteristics. The addition of ECi data during recovery periods of physical exercise provides currently missing physiological insights. Sleep quality monitoring, including detection of snoring episodes resulting from cellular hypoxia during sleep, is lacking in current technology fitness and SpO2 monitoring. When the disclosed sensor is applied to an athlete during sleep, the data generated can assess breathing during sleep and provide potentially relevant new insights into the recovery process in addition to information from existing monitoring methods.
[0189] Worker surveillance
[0190] In another example, the disclosed sensor may be used to provide continuous monitoring of workers in high risk breathing environments such as astronauts, divers, firefighters, underground miners, and workers in potentially toxic industrial environments where a pulse oximeter sensor cannot be worn or would not function properly or in a useful manner.
[0191] Pilot monitoring
[0192] In another example, the disclosed sensor may be used to provide continuous monitoring of military pilots flying high-performance aircraft in training and combat. It is well known that these pilots are at risk of hypoxia due to loss of cockpit air pressure at high altitudes. They are also at risk of loss of blood flow to the head when performing high-g load-inducing maneuvers of the aircraft. One or both of these threats may suddenly incapacitate the pilot without any indication of a failure in the aircraft system. Applying the disclosed sensor to the pilot's forehead will provide an immediate, objective indication of cellular hypoxia in the forehead skin or loss of blood flow in the skin, or both. If these physiological responses detected in the pilot are automatically communicated to the aircraft controller, an automatic pilot rescue process may be triggered to manipulate the aircraft to a stable, safe flight state and notify the command personnel of the emergency. If the pilot can regain control of the aircraft once the threat is automatically resolved, he / she can continue to perform the mission.
[0193] Although preferred embodiments of the present invention have been shown and described herein, it will be apparent to those skilled in the art that such embodiments are provided by way of example only. Without departing from the present invention, those skilled in the art will now appreciate many variations, changes and substitutions. It should be understood that in practicing the present invention, a variety of alternatives of the embodiments of the present invention described herein may be adopted. It is intended that the following claims define the scope of the present invention, and methods and structures within the scope of these claims and their equivalents are encompassed by the scope of the present invention.
Claims
1. An energy conversion monitor sensor, comprising: shell; Power source; a first light emitter positioned within the interior of the housing and configured to emit first light at a first wavelength; a second light emitter positioned within the interior of the housing and configured to emit second light at a second wavelength different from the first wavelength; a light detector positioned within the interior of the housing and optically isolated from the first light emitter and the second light emitter, wherein the light detector is configured to detect a resulting first tissue-interacted light signal from the first light emitter and a second tissue-interacted light signal from the second light emitter; a lighting power control circuit in communication with the first light emitter and the second light emitter, wherein the lighting power control circuit is configured to provide a lighting power defined by a computer program to activate the first light emitter and the second light emitter at a corresponding lighting intensity defined by the computer program; a signal amplifier in communication with the light detector; and a microcontroller configured to calculate a first output data value from the first light interacting with the tissue and a second output data value from the second light interacting with the tissue, wherein the microcontroller can be configured to compensate for changes in skin pigmentation levels during an initialization process by gradually increasing the power delivered to the first light emitter up to a sustainable maximum rated power level for the first light emitter, and Further, wherein if the detected intensity at 85% of full scale cannot be detected when the sustainable maximum rated power level for the first optical transmitter is reached, the microcontroller can be configured to implement an oversampling and mathematical integration method.
2. The energy conversion monitor sensor according to claim 1, characterized in that The energy conversion monitor sensor uses multiple wavelengths of light selected by in vivo spectrometry.
3. The energy conversion monitor sensor according to claim 2, characterized in that: The plurality of wavelengths of light are selected to maximize corresponding changes in detected cellular light absorbance relative to at least one of a known cellular biochemical phenomenon and a known physiological phenomenon affecting the monitored tissue.
4. The energy conversion monitor sensor according to claim 1, characterized in that The first light emitter has a first light emitter center wavelength value from 675 nm to 695 nm, inclusive.
5. The energy conversion monitor sensor according to claim 1, characterized in that The microcontroller can be configured to increase the number of burst samples beyond a nominal number, sum all of the burst sample values, and divide the sum of all of the burst samples by the nominal number until a calculated intensity value equal to or greater than 85% full scale is achieved.
6. The energy conversion monitor sensor according to claim 1, characterized in that The second light emitter has a second light emitter center wavelength value from 840 nm to 860 nm, inclusive.
7. The energy conversion monitor sensor according to claim 1, characterized in that The light detector detects the first tissue-interacting light signal and the second tissue-interacting light signal at one or more timed intervals.
8. A method of using an energy conversion monitor sensor, comprising the steps of: applying an energy conversion monitor sensor to a skin surface of a patient, wherein the energy conversion monitor sensor comprises: a housing; a power source; a first light emitter positioned within an interior of the housing and configured to emit a first light at a first wavelength; a second light emitter positioned within the interior of the housing and configured to emit a second light at a second wavelength different from the first wavelength; a light detector positioned within the interior of the housing and optically isolated from the first light emitter and the second light emitter, wherein the light detector is configured to detect a resulting first tissue-interacting light signal from the first light emitter and a second tissue-interacting light signal from the second light emitter; an illumination power control circuit in communication with the first light emitter and the second light emitter, wherein the illumination power control circuit is configured to provide a computer program-defined illumination power to excite the first light emitter and the second light emitter at corresponding computer program-defined illumination intensities; a signal amplifier in communication with the light detector; and a microcontroller configured to calculate a first output data value from the first tissue-interacting light and a second output data from the second tissue-interacting light; providing power to the energy conversion monitor sensor; delivering a power level to the energy conversion monitor sensor such that a first detected light intensity at a first wavelength between 675 nm and 695 nm, inclusive, is equal to a second detected light intensity at a second wavelength between 840 nm and 860 nm, inclusive; determining a first detected light intensity based on the first light signal interacting with the tissue; determining a second detected light intensity based on the second light signal interacting with the tissue; comparing the first detected light intensity to a first full scale to determine a first percentage detected light intensity; comparing the second detected light intensity to a second full scale to determine a second percentage detected light intensity; and The delivering, determining and comparing steps are repeated for each of the first detected light intensity and the second detected light intensity to obtain a detected light intensity at 85% of full scale.
9. The energy conversion monitor sensor method of claim 8, wherein: Further comprising the steps of: storing in a memory the power level of the detected integrated intensity of tissue-interacting light from the first light emitter to achieve 85% of full scale and a total number of burst samples added together and divided by a nominal number of burst samples; And storing in a memory the power level to achieve a detected intensity of tissue-interacting light from the second light emitter of 85% full scale.
10. The energy conversion monitor sensor method of claim 9, wherein: Further comprising the steps of: The stored power level of the first light emitter and the number of burst samples of detected light interacting with tissue from the first light emitter and the stored power level of the second light emitter are used as control parameters in data acquisition through the current recording session.
11. The energy conversion monitor sensor method of claim 8, wherein: Further comprising the steps of: Initializing the energy conversion monitor sensor; subtracting a detected intensity from the first light emitter after tissue interaction with a second light (between 840 nm and 860 nm, inclusive) from the second light emitter after tissue interaction with the first light (between 675 nm and 695 nm, inclusive) to produce an energy conversion index (ECi) output as at least 12 bits of resolution; as well as An integer numerical simulation indicative of the chemical state associated with cellular oxygen supply is generated.
12. The energy conversion monitor sensor method of claim 8, wherein: Further comprising the steps of: calculating one of a user's cellular oxygen supply correlation center and an energy conversion index zero (ECi zero); as well as An offset value is applied to the center of the energy conversion monitor sensor output data.
13. The energy conversion monitor sensor method of claim 8, wherein: Further comprising the steps of: performing a calculation averaging the low activity periods to define and record an offset value relative to zero; determining a current ECi zero point for the patient; as well as The recorded offset value is applied to center the recorded data about the patient's current ECi zero point.
14. The energy conversion monitor sensor method of claim 8, wherein: Further comprising the steps of: In response to ECi data less than zero resulting from decreased detection intensity at 685 nm and simultaneously stable detection intensity at 850 nm, less than physiologically optimal cellular oxygen supply is indicated.
15. The energy conversion monitor sensor method of claim 8, wherein: Further comprising the steps of: In response to ECi data greater than zero resulting from a stable or increasing first detected intensity between 675 nm and 695 nm, inclusive, and a stable or decreasing second detected intensity between 840 nm and 860 nm, inclusive, indicating cellular oxygen supply exceeding physiological optimality.
16. The energy conversion monitor sensor method of claim 8, wherein: Further comprising the steps of: Identifying an indication of a change in blood volume beneath the energy conversion monitor sensor, the blood volume change being caused by at least one of movement of the energy conversion monitor sensor against the skin and a change in body position relative to gravity during sleep, the change in body position relative to gravity causing a series change in a first detected light intensity between 675 nm and 695 nm, inclusive, and a second detected light intensity between 840 nm and 860 nm, inclusive.
17. The energy conversion monitor sensor method of claim 8, wherein: Further comprising the steps of: generating a signal between 840 nm and 860 nm, inclusive; as well as The generated signal is detected at sufficiently frequent time intervals to define the amplitude and waveform of the respiratory induced light intensity changes as an indication of one of increased effort to breathe through a restricted or obstructed airway and decreased or absent respiratory effort from decreased or absent central nervous system respiratory drive.
18. The energy conversion monitor sensor method of claim 8, wherein: Further comprising the steps of: applying the energy conversion monitor sensor to a person identified as possibly suffering from sleep disordered breathing (SDB); monitoring breathing and oxygen supply related physiological functions during sleep of the person; as well as Recorded data from such monitoring is provided to assist in the clinical diagnosis of SDB, thereby helping to define, validate and adjust effective treatments.
19. The energy conversion monitor sensor method of claim 8, wherein: Further comprising the steps of: applying the energy conversion monitor sensor to a person with sleep disordered breathing (SDB) while sleeping at home while using an SDB treatment device; and A management scope of the SDB is determined.
20. The energy conversion monitor sensor method of claim 8, wherein: Further comprising the steps of: applying the energy conversion monitor sensor to a person identified as being at risk for developing sepsis; as well as The possible presence of sepsis is detected by an ECi value that gradually tends to be less than zero.
21. The energy conversion monitor sensor method of claim 8, wherein: Further comprising the steps of: applying the energy conversion monitor sensor to an infant; and The infants were screened for SIDS risk by recording the stability and effectiveness of their breathing during sleep.
22. The energy conversion monitor sensor method of claim 8, wherein: Further comprising the steps of: applying the energy conversion monitor sensor to an infant; Monitors the stability and effectiveness of breathing during sleep; as well as One or more of delivering stimulation during an abnormal breathing episode detected during sleep to awaken the infant from sleep and delivering an alert to a caregiver identifying the detected abnormal breathing.
23. The energy conversion monitor sensor method of claim 8, wherein: Further comprising the steps of: Applying the energy conversion monitor sensor to workers in high-risk atmospheric environments; as well as The worker is monitored for at least one of hypoxia and adverse effects of toxic gases in the air the worker breathes.
24. The energy conversion monitor sensor method of claim 8, wherein: Further comprising the steps of: applying the energy conversion monitor sensor to the pilot's forehead; and The pilot is monitored for one or more of hypoxia and g-load induced loss of blood flow to the head.
25. The energy conversion monitor sensor method of claim 8, wherein: Further comprising the steps of: applying the energy conversion monitor sensor to an athlete during and after physical exercise; assessing a physiological response of the athlete; and Provides suggestions for optimal performance.
26. The energy conversion monitor sensor method of claim 8, wherein: Further comprising the steps of: applying said energy conversion monitor sensor with dual probes to the chest and abdomen of infant patients in intensive care; Monitoring of preductal and postductal cellular oxygen supply; and At least one of an anatomical abnormality of the heart, an anatomical abnormality of the great vessels, and failure of the ductus arteriosus to close properly is detected.
27. The energy conversion monitor sensor method of claim 8, wherein: Further comprising the steps of: The energy conversion monitor sensor with dual probes is applied during at least one of myocardial reperfusion during treatment of ischemic heart attack, reperfusion of affected areas of the brain during treatment of stroke, reperfusion of transplanted organs, and directed oxygen resupply to ischemic tissue relative to cellular oxygen demand to help reduce or prevent reperfusion injury.
28. An energy conversion monitoring system comprising: An energy conversion monitor sensor comprising: a housing; a power source; a first light emitter positioned within an interior of the housing and configured to emit a first light at a first wavelength; a second light emitter positioned within the interior of the housing and configured to emit a second light at a second wavelength different from the first intensity; a light detector positioned within the interior of the housing and optically isolated from the first light emitter and the second light emitter, wherein the light detector is configured to detect a resulting first tissue-interacting light signal from the first light emitter and a second tissue-interacting light signal from the second light emitter; an illumination power control circuit in communication with the first light emitter and the second light emitter, wherein the illumination power control circuit is configured to provide an illumination power defined by a computer program to exciting the first light emitter and the second light emitter at an illumination intensity defined by a corresponding computer program; a signal amplifier in communication with the light detector; and a microcontroller configured to calculate a first output data value from the first light interacting with the tissue and a second output data from the second light interacting with the tissue, wherein the microcontroller can be configured to compensate for changes in skin pigmentation levels during an initialization process by gradually increasing the power delivered to the first light emitter up to a sustainable maximum rated power level for the first light emitter, and further, wherein if a detection intensity at 85% of full scale cannot be detected when the sustainable maximum rated power level for the first light emitter is reached, the microcontroller can be configured to implement an oversampling and mathematical integration method; and At least one auxiliary device selected from: A second sensor, a sleep disordered breathing (SDB) treatment device, a remote computing device, and a polysomnography (PSG) system.
